



- (51) International Patent Classification:
C12Q 1/68 (2006.01)
- (21) International Application Number:
PCT/EP2016/067440
- (22) International Filing Date:
21 July 2016 (21.07.2016)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
PCT/EP2015/066658 21 July 2015 (21.07.2015) EP
- (71) Applicant: **CURETIS GMBH** [DE/DE]; Max-Eyth-Strasse 42, 71088 Holzgerlingen (DE).
- (72) Inventors: **SCHMOLKE, Susanne**; Gebbertstrasse 37, 91052 Erlangen (DE). **STÄHLER, Cord, Friedrich**; Muldweg 8, 69493 Hirschberg an der Bergstrasse (DE). **KELLER, Andreas**; Albert Schweitzer Str. 6, 66346 Püttlingen (DE). **BACKES, Christina**; Am Geisenberg 45, 66125 Saarbrücken (DE).
- (74) Agent: **SCHNAPPAUF, Georg**; ZSP Patentanwälte PartG mbB, Radlkofnerstrasse 2, 81373 München (DE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))



WO 2017/013219 A2

(54) Title: GENETIC TESTING FOR PREDICTING RESISTANCE OF GRAM-NEGATIVE PROTEUS AGAINST ANTIMICROBIAL AGENTS



(57) Abstract: The invention relates to a method of determining an infection of a patient with Proteus species potentially resistant to antimicrobial drug treatment, a method of selecting a treatment of a patient suffering from an antibiotic resistant Proteus infection, and a method of determining an antibiotic resistance profile for bacterial microorganisms of Proteus species, as well as computer program products used in these methods. In an exemplary method, a sample 1, is used for molecular testing 2, and then a molecular fingerprint 3 is taken. The result is then compared to a reference library 4, and the result 5 is reported.

Genetic testing for predicting resistance of Gram-negative Proteus against antimicrobial agents

The present invention relates to a method of determining an
5 infection of a patient with Proteus species potentially re-
sistant to antimicrobial drug treatment, a method of select-
ing a treatment of a patient suffering from an infection with
a potentially resistant Proteus strain, and a method of de-
termining an antimicrobial drug, e.g. antibiotic, resistance
10 profile for bacterial microorganisms of Proteus species, as
well as computer program products used in these methods.

Antibiotic resistance is a form of drug resistance whereby a
15 sub-population of a microorganism, e.g. a strain of a bacte-
rial species, can survive and multiply despite exposure to an
antibiotic drug. It is a serious and health concern for the
individual patient as well as a major public health issue.
Timely treatment of a bacterial infection requires the analy-
20 sis of clinical isolates obtained from patients with regard
to antibiotic resistance, in order to select an efficacious
therapy. Generally, for this purpose an association of the
identified resistance with a certain microorganism (i.e. ID)
is necessary.

25

Antibacterial drug resistance (ADR) represents a major health
burden. According to the World Health Organization's antimi-
crobial resistance global report on surveillance, ADR leads
to 25,000 deaths per year in Europe and 23,000 deaths per
30 year in the US. In Europe, 2.5 million extra hospital days
lead to societal cost of 1.5 billion euro. In the US, the di-
rect cost of 2 million illnesses leads to 20 billion dollar
direct cost. The overall cost is estimated to be substantial-

ly higher, reducing the gross domestic product (GDP) by up to 1.6%.

Proteus is a genus of Gram-negative Proteobacteria. Proteus bacilli are widely distributed in nature as saprophytes, being found in decomposing animal matter, in sewage, in manure soil, and in human and animal feces. They are opportunistic pathogens, commonly responsible for urinary and septic infections.

10

In general the mechanisms for resistance of bacteria against antimicrobial treatments rely to a very substantial part on the organism's genetics. The respective genes or molecular mechanisms are either encoded in the genome of the bacteria or on plasmids that can be interchanged between different bacteria. The most common resistance mechanisms include:

15

- 1) Efflux pumps are high-affinity reverse transport systems located in the membrane that transports the antibiotic out of the cell, e.g. resistance to tetracycline.

20

- 2) Specific enzymes modify the antibiotic in a way that it loses its activity. In the case of streptomycin, the antibiotic is chemically modified so that it will no longer bind to the ribosome to block protein synthesis.

25

- 3) An enzyme is produced that degrades the antibiotic, thereby inactivating it. For example, the penicillinases are a group of beta-lactamase enzymes that cleave the beta lactam ring of the penicillin molecule.

30

In addition, some pathogens show natural resistance against drugs. For example, an organism can lack a transport system for an antibiotic or the target of the antibiotic molecule is not present in the organism. In the case of Gram-negative bacteria, the cell wall is covered with an outer membrane

that may establish a permeability barrier against the antibiotic.

Pathogens that are in principle susceptible to drugs can become resistant by modification of existing genetic material (e.g. spontaneous mutations for antibiotic resistance, happening in a frequency of one in about 100 mio bacteria in an infection) or the acquisition of new genetic material from another source. One example is horizontal gene transfer, a process where genetic material contained in small packets of DNA can be transferred between individual bacteria of the same species or even between different species. Horizontal gene transfer may happen by transduction, transformation or conjugation.

15

Generally, testing for susceptibility/resistance to antimicrobial agents is performed by culturing organisms in different concentration of these agents.

In brief, agar plates are inoculated with patient sample (e.g. urine, sputum, blood, stool) overnight. On the next day individual colonies are used for identification of organisms, either by culturing or using mass spectroscopy. Based on the identity of organisms new plates containing increasing concentration of drugs used for the treatment of these organisms are inoculated and grown for additional 12 - 24 hours. The lowest drug concentration which inhibits growth (minimal inhibitory concentration - MIC) is used to determine susceptibility/resistance for tested drugs. The process takes at least 2 to 3 working days during which the patient is treated empirically. A significant reduction of time-to-result is needed especially in patients with life-threatening disease and to overcome the widespread misuse of antibiotics.

Recent developments include PCR based test kits for fast bacterial identification (e.g. Biomerieux Biofire Tests, Curetis Unyvero Tests). With these test the detection of selected resistance loci is possible for a very limited number of drugs, but no correlation to culture based AST is given. Mass spectroscopy is increasingly used for identification of pathogens in clinical samples (e.g. Bruker Biotyper), and research is ongoing to establish methods for the detection of susceptibility/resistance against antibiotics.

10

For some drugs such it is known that at least two targets are addressed, e.g. in case of Ciprofloxacin (drug bank ID 00537; <http://www.drugbank.ca/drugs/DB00537>) targets include DNA Topoisomerase IV, DNA Topoisomerase II and DNA Gyrase. It can be expected that this is also the case for other drugs although the respective secondary targets have not been identified yet. In case of a common regulation, both relevant genetic sites would naturally show a co-correlation or redundancy.

20

It is known that drug resistance can be associated with genetic polymorphisms. This holds for viruses, where resistance testing is established clinical practice (e.g. HIV genotyping). More recently, it has been shown that resistance has also genetic causes in bacteria and even higher organisms, such as humans where tumors resistance against certain cytostatic agents can be linked to genomic mutations.

25

Wozniak et al. (BMC Genomics 2012, 13(Suppl 7):S23) disclose genetic determinants of drug resistance in *Staphylococcus aureus* based on genotype and phenotype data. Stoesser et al. disclose prediction of antimicrobial susceptibilities for *Escherichia coli* and *Klebsiella pneumoniae* isolates using

30

whole genomic sequence data (J Antimicrob Chemother 2013; 68: 2234-2244).

Chewapreecha et al (Chewapreecha et al (2014) Comprehensive
5 Identification of single nucleotid polymorphisms associated
with beta-lactam resistance within pneumococcal mosaic genes.
PLoS Genet 10(8): e1004547) used a comparable approach to
identify mutations in gram-positive Streptococcus Pneumonia.

10 The fast and accurate detection of infections with Proteus
species and the prediction of response to anti-microbial
therapy represent a high unmet clinical need.

This need is addressed by the present invention.

15

Summary of the Invention

The present inventors addressed this need by carrying out
whole genome sequencing of a large cohort of Proteus clinical
20 isolates and comparing the genetic mutation profile to clas-
sical culture based antimicrobial susceptibility testing with
the goal to develop a test which can be used to detect bacte-
rial susceptibility/resistance against antimicrobial drugs
using molecular testing.

25

The inventors performed extensive studies on the genome of
bacteria of Proteus species either susceptible or resistant
to antimicrobial, e.g. antibiotic, drugs. Based on this in-
formation, it is now possible to provide a detailed analysis
30 on the resistance pattern of Proteus strains based on indi-
vidual genes or mutations on a nucleotide level. This analy-
sis involves the identification of a resistance against indi-
vidual antimicrobial, e.g. antibiotic, drugs as well as clus-
ters of them. This allows not only for the determination of a
35 resistance to a single antimicrobial, e.g. antibiotic, drug,

but also to groups of antimicrobial drugs, e.g. antibiotics such as lactam or quinolone antibiotics, or even to all relevant antibiotic drugs.

5 Therefore, the present invention will considerably facilitate the selection of an appropriate antimicrobial, e.g. antibiotic, drug for the treatment of a Proteus infection in a patient and thus will largely improve the quality of diagnosis and treatment.

10

According to a first aspect, the present invention discloses a diagnostic method of determining an infection of a patient with Proteus species potentially resistant to antimicrobial drug treatment, which can be also described as a method of
15 determining an antimicrobial drug, e.g. antibiotic, resistant Proteus infection of a patient, comprising the steps of:

a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;
b) determining the presence of at least one mutation in at
20 least two genes from the group of genes listed in Table 1 or Table 2 below, wherein the presence of said at least two mutations is indicative of an infection with an antimicrobial drug resistant, e.g. antibiotic resistant, Proteus strain in said patient.

25

An infection of a patient with Proteus species potentially resistant to antimicrobial drug treatment herein means an infection of a patient with Proteus species wherein it is unclear if the Proteus species is susceptible to treatment with
30 a specific antimicrobial drug or if it is resistant to the antimicrobial drug.

In step b) above, as well as corresponding steps, at least one mutation in at least two genes is determined, so that in

total at least two mutations are determined, wherein the two mutations are in different genes.

Table 1: List of genes

parC	secG	cyoC	pykF	flhB
dedA	crr	murF	gmhB	purH
PMI2939	fdoG	PMI3715	gpmB	

5

Table 2: List of genes

parC	secG	cyoC	pykF	flhB
dedA	crr	murF	gmhB	purH
PMI2939	fdoG	PMI3715	gpmB	

According to a second aspect, the present invention relates to a method of selecting a treatment of a patient suffering from an infection with a potentially resistant Proteus stain, e.g. from an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:

10

a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;

15

b) determining the presence of at least one mutation in at least two genes from the group of genes listed in Table 1 or Table 2 above, wherein the presence of said at least two mutations is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;

20

c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and

d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.

25

A third aspect of the present invention relates to a method of determining an antimicrobial drug, e.g. antibiotic, re-

sistance profile for bacterial microorganisms of *Proteus* species, comprising:

obtaining or providing a first data set of gene sequences of a plurality of clinical isolates of *Proteus* species;

5 providing a second data set of antimicrobial drug, e.g. antibiotic, resistance of the plurality of clinical isolates of *Proteus* species;

aligning the gene sequences of the first data set to at least one, preferably one, reference genome of *Proteus*, and/or assembling the gene sequence of the first data set, at least in
10 part;

analyzing the gene sequences of the first data set for genetic variants to obtain a third data set of genetic variants;

correlating the third data set with the second data set and
15 statistically analyzing the correlation; and

determining the genetic sites in the genome of *Proteus* associated with antimicrobial drug, e.g. antibiotic, resistance.

In addition, the present invention relates in a fourth aspect
20 to a method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for a bacterial microorganism belonging to the species *Proteus* comprising the steps of

a) obtaining or providing a sample containing or suspected of containing the bacterial microorganism;

25 b) determining the presence of a mutation in at least one gene of the bacterial microorganism as determined by the method according to the third aspect of the present invention;

wherein the presence of a mutation is indicative of a resistance to an antimicrobial, e.g. antibiotic, drug.
30

Furthermore, the present invention discloses in a fifth aspect a diagnostic method of determining an infection of a pa-

tient with *Proteus* species potentially resistant to antimicrobial drug treatment, which can, like in the first aspect, also be described as method of determining an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection of a patient, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing a bacterial microorganism belonging to the species *Proteus* from the patient;
- b) determining the presence of at least one mutation in at least one gene of the bacterial microorganism belonging to the species *Proteus* as determined by the method according to the third aspect of the present invention, wherein the presence of said at least one mutation is indicative of an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection in said patient.

Also disclosed is in a sixth aspect a method of selecting a treatment of a patient suffering from an infection with a potentially resistant *Proteus* strain, e.g. from an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing a bacterial microorganism belonging to the species *Proteus* from the patient;
- b) determining the presence of at least one mutation in at least one gene of the bacterial microorganism belonging to the species *Proteus* as determined by the method according to the third aspect of the present invention, wherein the presence of said at least one mutation is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and

d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.

5 A seventh aspect of the present invention relates to a method of acquiring, respectively determining, an antimicrobial drug, e.g. antibiotic, resistance profile for a bacterial microorganism of Proteus species, comprising:
obtaining or providing a first data set of gene sequences of
10 a clinical isolate of Proteus species;
providing a second data set of antimicrobial drug, e.g. antibiotic, resistance of a plurality of clinical isolates of Proteus species;
aligning the gene sequences of the first data set to at least
15 one, preferably one, reference genome of Proteus, and/or assembling the gene sequence of the first data set, at least in part;
analyzing the gene sequences of the first data set for genetic variants to obtain a third data set of genetic variants of
20 the first data set;
correlating the third data set with the second data set and statistically analyzing the correlation; and
determining the genetic sites in the genome of Proteus of the first data set associated with antimicrobial drug, e.g. anti-
25 biotic, resistance.

According to an eighth aspect, the present invention discloses a computer program product comprising executable instructions which, when executed, perform a method according to the
30 third, fourth, fifth, sixth or seventh aspect of the present invention.

Further aspects and embodiments of the invention are disclosed in the dependent claims and can be taken from the following description, figures and examples, without being limited thereto.

5

Figures

The enclosed drawings should illustrate embodiments of the present invention and convey a further understanding thereof.

10

In connection with the description they serve as explanation of concepts and principles of the invention. Other embodiments and many of the stated advantages can be derived in relation to the drawings. The elements of the drawings are not necessarily to scale towards each other. Identical, functionally equivalent and acting equal features and components are denoted in the figures of the drawings with the same reference numbers, unless noted otherwise.

15

Fig. 1 shows schematically a read-out concept for a diagnostic test according to a method of the present invention.

20

Detailed description of the present invention

Definitions

25

Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

30

An "antimicrobial drug" in the present invention refers to a group of drugs that includes antibiotics, antifungals, antiprotozoals, and antivirals. According to certain embodiments, the antimicrobial drug is an antibiotic.

The term "nucleic acid molecule" refers to a polynucleotide molecule having a defined sequence. It comprises DNA molecules, RNA molecules, nucleotide analog molecules and combinations and derivatives thereof, such as DNA molecules or RNA molecules with incorporated nucleotide analogs or cDNA.

The term "nucleic acid sequence information" relates to information which can be derived from the sequence of a nucleic acid molecule, such as the sequence itself or a variation in the sequence as compared to a reference sequence.

The term "mutation" relates to a variation in the sequence as compared to a reference sequence. Such a reference sequence can be a sequence determined in a predominant wild type organism or a reference organism, e.g. a defined and known bacterial strain or substrain. A mutation is for example a deletion of one or multiple nucleotides, an insertion of one or multiple nucleotides, or substitution of one or multiple nucleotides, duplication of one or a sequence of multiple nucleotides, translocation of one or a sequence of multiple nucleotides, and, in particular, a single nucleotide polymorphism (SNP).

In the context of the present invention a "sample" is a sample which comprises at least one nucleic acid molecule from a bacterial microorganism. Examples for samples are: cells, tissue, body fluids, biopsy specimens, blood, urine, saliva, sputum, plasma, serum, cell culture supernatant, swab sample and others. According to certain embodiments, the sample is a patient sample (clinical isolate).

New and highly efficient methods of sequencing nucleic acids referred to as next generation sequencing have opened the

possibility of large scale genomic analysis. The term "next generation sequencing" or "high throughput sequencing" refers to high-throughput sequencing technologies that parallelize the sequencing process, producing thousands or millions of
5 sequences at once. Examples include Massively Parallel Signature Sequencing (MPSS), Polony sequencing, 454 pyrosequencing, Illumina (Solexa) sequencing, SOLiD sequencing, Ion semiconductor sequencing, DNA nanoball sequencing, Helioscope(TM) single molecule sequencing, Single Molecule
10 SMRT(TM) sequencing, Single Molecule real time (RNAP) sequencing, Nanopore DNA sequencing, Sequencing By Hybridization, Amplicon Sequencing, GnuBio.

Within the present description the term "microorganism" comprises the term microbe. The type of microorganism is not particularly restricted, unless noted otherwise or obvious, and, for example, comprises bacteria, viruses, fungi, microscopic algae und protozoa, as well as combinations thereof. According to certain aspects, it refers to one or more Proteus species, particularly Proteus mirabilis, Proteus penneri
20 and/or Proteus vulgaris.

A reference to a microorganism or microorganisms in the present description comprises a reference to one microorganism
25 as well a plurality of microorganisms, e.g. two, three, four, five, six or more microorganisms.

A vertebrate within the present invention refers to animals having a vertebrae, which includes mammals - including humans, birds, reptiles, amphibians and fishes. The present invention thus is not only suitable for human medicine, but also for veterinary medicine.
30

According to certain embodiments, the patient in the present methods is a vertebrate, more preferably a mammal and most preferred a human patient.

5 Before the invention is described in exemplary detail, it is to be understood that this invention is not limited to the particular component parts of the process steps of the methods described herein as such methods may vary. It is also to be understood that the terminology used herein is for purposes
10 of describing particular embodiments only, and is not intended to be limiting. It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include singular and/or plural referents unless the context clearly dictates otherwise. For example,
15 the term "a" as used herein can be understood as one single entity or in the meaning of "one or more" entities. It is also to be understood that plural forms include singular and/or plural referents unless the context clearly dictates otherwise. It is moreover to be understood that, in case parameter
20 ranges are given which are delimited by numeric values, the ranges are deemed to include these limitation values.

Regarding the dosage of the antimicrobial, e.g. antibiotic, drugs, it is referred to the established principles of pharmacology in human and veterinary medicine. For example,
25 Forth, Henschler, Rummel "Allgemeine und spezielle Pharmakologie und Toxikologie", 9th edition, 2005, pp. 781 - 919, might be used as a guideline. Regarding the formulation of a ready-to-use medicament, reference is made to "Remington,
30 ton, The Science and Practice of Pharmacy", 22nd edition, 2013, pp. 777 - 1070.

Assembling of a gene sequence can be carried out by any known method and is not particularly limited.

According to certain embodiments, mutations that were found using alignments can also be compared or matched with alignment-free methods, e.g. for detecting single base exchanges, for example based on contigs that were found by assemblies. For example, reads obtained from sequencing can be assembled to contigs and the contigs can be compared to each other.

10 According to a first aspect, the present invention relates to a diagnostic method of determining an infection of a patient with *Proteus* species potentially resistant to antimicrobial drug treatment, which can also be described as method of determining an antimicrobial drug, e.g. antibiotic, resistant

15 *Proteus* infection of a patient, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
- b) determining the presence of at least one mutation in at least two genes from the group of genes consisting of *parC*,

20 *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, and *gpmB*, preferably *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, and *gpmB*, wherein the presence of said at least two mutations is indicative of an infection with an antimicrobial, e.g. anti-

25 biotic, resistant *Proteus* strain in said patient.

In this method, as well as the other methods of the invention, the sample can be provided or obtained in any way, preferably non-invasive, and can be e.g. provided as an *in vitro* sample or prepared as *in vitro* sample.

According to certain aspects, mutations in at least two, three, four, five, six, seven, eight, nine or ten genes are

determined in any of the methods of the present invention, e.g. in at least two genes or in at least three genes. Instead of testing only single genes or mutants, a combination of several variant positions can improve the prediction accuracy and further reduce false positive findings that are influenced by other factors. Therefore, it is in particular preferred to determine the presence of a mutation in 2, 3, 4, 5, 6, 7, 8 or 9 (or more) genes selected from Table 1 or 2.

10 For the above genes, i.e. the genes also denoted in Tables 1 and 2, the highest probability of a resistance to at least one antimicrobial drug, e.g. antibiotic, could be observed, with p-values smaller than 10^{-30} , particularly smaller than 10^{-40} , further particularly smaller than 10^{-60} , indicating the high significance of the values ($n=583$; $\alpha=0.05$). Details regarding Tables 1 and 2 can be taken from Tables 3 and 4 (4a, 4b, 4c) disclosed in the Examples. Having at least two genes with mutations determined, a high probability of an antimicrobial drug, e.g. antibiotic, resistance could be determined. The genes in Table 1 thereby represent the best genes for which a mutation was observed in the genomes of Proteus species, whereas the genes in Table 2 represent the best genes for which a cross-correlation could be observed for the antimicrobial drug, e.g. antibiotic, susceptibility testing for Proteus species as described below.

According to certain embodiments, the obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient in this method - as well as the other methods of the invention - can comprise the following:

A sample of a vertebrate, e.g. a human, e.g. is provided or obtained and nucleic acid sequences, e.g. DNA or RNA sequenc-

es, are recorded by a known method for recording nucleic acid, which is not particularly limited. For example, nucleic acid can be recorded by a sequencing method, wherein any sequencing method is appropriate, particularly sequencing methods wherein a multitude of sample components, as e.g. in a blood sample, can be analyzed for nucleic acids and/or nucleic acid fragments and/or parts thereof contained therein in a short period of time, including the nucleic acids and/or nucleic acid fragments and/or parts thereof of at least one microorganism of interest, particularly of at least one *Proteus* species. For example, sequencing can be carried out using polymerase chain reaction (PCR), particularly multiplex PCR, or high throughput sequencing or next generation sequencing, preferably using high-throughput sequencing. For sequencing, preferably an *in vitro* sample is used.

The data obtained by the sequencing can be in any format, and can then be used to identify the nucleic acids, and thus genes, of the microorganism, e.g. of *Proteus* species, to be identified, by known methods, e.g. fingerprinting methods, comparing genomes and/or aligning to at least one, or more, genomes of one or more species of the microorganism of interest, i.e. a reference genome, etc., forming a third data set of aligned genes for a *Proteus* species - discarding additional data from other sources, e.g. the vertebrate. Reference genomes are not particularly limited and can be taken from several databases. Depending on the microorganism, different reference genomes or more than one reference genomes can be used for aligning. Using the reference genome - as well as also the data from the genomes of the other species, e.g. *Proteus* species - mutations in the genes for each species and for the whole multitude of samples of different species, e.g. *Proteus* species, can be obtained.

For example, it is useful in genome-wide association studies to reference the points of interest, e.g. mutations, to one constant reference for enhanced standardization. In case of
5 the human with a high consistency of the genome and 99% identical sequences among individuals this is easy and represents the standard, as corresponding reference genomes are available in databases. In case of organisms that trigger infectious diseases (e.g. bacteria and viruses) this is much more
10 difficult, though. One possibility is to fall back on a virtual pan genome which contains all sequences of a certain genus. A further possibility is the analysis of all available references, which is much more complex. Therein all n references from a database (e.g. RefSeq) are extracted and compared with the newly sequenced bacterial genomes k . After
15 this, matrices (% of mapped reads, % of covered genome) are applied to estimate which reference is best suited to all new bacteria. However, $n \times k$ complete alignments are carried out. Having a big number of references, though, stable results can
20 be obtained, as is the case for Proteus.

According to certain embodiments, the genomes of Proteus species are referenced to one reference genome. However, it is not excluded that for other microorganisms more than one reference genome is used. In the present methods, the reference
25 genome of Proteus is NC_010554 as annotated at the NCBI according to certain embodiments. The reference genome is attached to this application as sequence listing with SEQ ID NO
1.

30

The reference sequence was obtained from Proteus strain NC_010554 (http://www.genome.jp/dbget-bin/www_bget?refseq+NC_010554)

LOCUS NC_010554 4063606 bp DNA circular CON 07-FEB-2015
DEFINITION Proteus mirabilis strain HI4320, complete genome.
ACCESSION NC_010554
VERSION NC_010554.1 GI:197283915
5 DBLINK BioProject: PRJNA224116
Assembly: GCF_000069965.1
KEYWORDS RefSeq; complete genome.
SOURCE Proteus mirabilis HI4320
ORGANISM Proteus mirabilis HI4320
10 Bacteria; Proteobacteria; Gammaproteobacteria;
Enterobacteriales; Enterobacteriaceae; Proteus.
REFERENCE 1
AUTHORS Pearson,M.M., Sebahia,M., Churcher,C.,
Quail,M.A., Seshasayee,A.S., Luscombe,N.M., Abdellah,Z.,
15 Arrosmith,C., Atkin,B., Chillingworth,T., Hauser,H., Ja-
gels,K., Moule,S., Mungall,K., Norbertczak,H., Rabbino-
witsch,E., Walker,D., Whithead,S., Thomson,N.R., Rather,P.N.,
Parkhill,J. and Mobley,H.L.
TITLE Complete genome sequence of uropathogenic Proteus
20 mirabilis, a master of both adherence and motility
JOURNAL J. Bacteriol. 190 (11), 4027-4037 (2008)
PUBMED 18375554
REFERENCE 2 (bases 1 to 4063606)
AUTHORS Sebahia,M.
25 TITLE Direct Submission
JOURNAL Submitted (18-FEB-2008) Sebahia M., Sulston La-
boratories, Wellcome Trust Sanger Institute, Wellcome Trust
Genome Campus, Hinxton, Cambridge, CB10 1SA, UNITED KINGDOM
30 Alternatively or in addition, the gene sequence of the first
data set can be assembled, at least in part, with known meth-
ods, e.g. by de-novo assembly or mapping assembly. The se-
quence assembly is not particularly limited, and any known

genome assembler can be used, e.g. based on Sanger, 454, Solexa, Illumina, SOLid technologies, etc., as well as hybrids/mixtures thereof.

5 According to certain embodiments, the data of nucleic acids of different origin than the microorganism of interest, e.g. Proteus species, can be removed after the nucleic acids of interest are identified, e.g. by filtering the data out. Such data can e.g. include nucleic acids of the patient, e.g. the
10 vertebrate, e.g. human, and/or other microorganisms, etc. This can be done by e.g. computational subtraction, as developed by Meyerson et al. 2002. For this, also aligning to the genome of the vertebrate, etc., is possible. For aligning, several alignment-tools are available. This way the original
15 data amount from the sample can be drastically reduced.

Also after such removal of "excess" data, fingerprinting and/or aligning, and/or assembly, etc. can be carried out, as described above, forming a third data set of aligned or as-
20 sembled genes for a Proteus species.

Using these techniques, genes with mutations of the microorganism of interest, e.g. Proteus species, can be obtained for various species.
25

When testing these same species for antimicrobial drug, e.g. antibiotic, susceptibility of a number of antimicrobial drugs, e.g. antibiotics, e.g. using standard culturing methods on dishes with antimicrobial drug, e.g. antibiotic, in-
30 take, as e.g. described below, the results of these antimicrobial drug, e.g. antibiotic, susceptibility tests can then be cross-referenced/correlated with the mutations in the genome of the respective microorganism, e.g. Proteus. Using several, e.g. 50 or more than 50, 100 or more than 100, 200

or more than 200, 300 or more than 300, 400 or more than 400,
or 450 or more than 450 different species of a microorganism,
e.g. different Proteus species, statistical analysis can be
carried out on the obtained cross-referenced data between mu-
5 tations and antimicrobial drug, e.g. antibiotic, susceptibil-
ity for these number of species, using known methods.

Regarding culturing methods, samples can be e.g. cultured
overnight. On the next day individual colonies can be used
10 for identification of organisms, either by culturing or using
mass spectroscopy. Based on the identity of organisms new
plates containing increasing concentration of antibiotics
used for the treatment of these organisms are inoculated and
grown for additional 12 - 24 hours. The lowest drug concen-
15 tration which inhibits growth (minimal inhibitory concentra-
tion - MIC) can be used to determine susceptibil-
ity/resistance for tested antibiotics.

Correlation of the nucleic acid / gene mutations with antimi-
20 crobial drug, e.g. antibiotic, resistance can be carried out
in a usual way and is not particularly limited. For example,
resistances can be correlated to certain genes or certain mu-
tations, e.g. SNPs, in genes. After correlation, statistical
analysis can be carried out.

25 In addition, statistical analysis of the correlation of the
gene mutations with antimicrobial drug, e.g. antibiotic, re-
sistance is not particularly limited and can be carried out,
depending on e.g. the amount of data, in different ways, for
30 example using analysis of variance (ANOVA) or Student's t-
test, for example with a sample size n of 50 or more, 100 or
more, 200 or more, 300 or more, 400 or more or 450 or more,
and a level of significance (α -error-level) of e.g. 0.05 or
smaller, e.g. 0.05, preferably 0.01 or smaller. A statistical
35 value can be obtained for each gene and/or each position in

the genome as well as for all antibiotics tested, a group of antibiotics or a single antibiotic. The obtained p-values can also be adapted for statistical errors, if needed.

5 For statistically sound results a multitude of individuals should be sampled, with $n = 50, 100, 200, 300, 400, 500$ or 550, and a level of significance (α -error-level) of e.g. 0.05 or smaller, e.g. 0.05, preferably 0.01 or smaller. According to certain embodiments, particularly significant results can
10 be obtained for $n = 200, 300, 400, 500$ or 550.

According to certain embodiments, a multitude of individuals can be sampled, with $n = 50$ or more, 100 or more, 200 or more, 300 or more, 400 or more, 500 or more or 550 or more,
15 and a level of significance (α -error-level) of e.g. 0.05 or smaller, e.g. 0.05, preferably 0.01 or smaller. According to certain embodiments, particularly significant results can be obtained for $n = 200$ or more, 300 or more, 400 or more, 500 or more or 550 or more.

20

After the above procedure has been carried out for more than 550, e.g. 583, individual species of *Proteus*, the data disclosed in Tables 1 and 2 were obtained for the statistically best correlations between gene mutations and antimicrobial
25 drug, e.g. antibiotic, resistances. Thus, mutations in these genes were proven as valid markers for antimicrobial drug, e.g. antibiotic, resistance.

According to a further aspect, the present invention relates
30 in a second aspect to a method of selecting a treatment of a patient suffering from an infection with a potentially resistant *Proteus* strain, e.g. from an antimicrobial drug, e.g.

antibiotic, resistant *Proteus* infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
- 5 b) determining the presence of at least one mutation in at least two genes from the group of genes consisting of *parC*, *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, and *gpmB*, preferably *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, and
10 *gpmB*, wherein the presence of said at least two mutations is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and
- 15 d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a *Proteus* infection.

In this method, the steps a) of obtaining or providing a sam-
20 ple and b) of determining the presence of at least one mutation are as in the method of the first aspect.

The identification of the at least one or more antimicrobial, e.g. antibiotic, drug in step c) is then based on the results
25 obtained in step b) and corresponds to the antimicrobial, e.g. antibiotic, drug(s) that correlate(s) with the mutations. Once these antimicrobial drugs, e.g. antibiotics, are ruled out, the remaining antimicrobial drugs, e.g. antibiotic drugs/antibiotics, can be selected in step d) as being suitable
30 for treatment.

In the description, references to the first and second aspect also apply to the 14th, 15th, 16th and 17th aspect, referring

to the same genes, unless clear from the context that they don't apply.

According to certain embodiments in the method of the first
5 or second aspect, at least a mutation in *parC*, particularly
in position 2562578 with regard to reference genome NC_010554
as annotated at the NCBI, is determined. For such mutation, a
particularly relevant correlation with antimicrobial drug,
e.g. antibiotic, resistance could be determined. In particu-
10 lar, the mutation in position 2562578 with regard to refer-
ence genome NC_010554 as annotated at the NCBI is a non-
synonymous coding, particularly a codon change aGc/aTc.

According to certain embodiments, the antimicrobial drug,
15 e.g. antibiotic, in the method of the first or second aspect,
as well as in the other methods of the invention, is at least
one selected from the group of β -lactams, β -lactam inhibi-
tors, quinolones and derivatives thereof, aminoglycosides,
polyketides, respectively tetracyclines, and folate synthesis
20 inhibitors.

In the methods of the invention the resistance of *Proteus* to
one or more antimicrobial, e.g. antibiotic, drugs can be de-
termined according to certain embodiments.

25

According to certain embodiments of the first and/or second
aspect of the invention the antimicrobial, e.g. antibiotic,
drug is selected from lactam antibiotics and the presence of
a mutation in the following genes is determined: *parC*, *secG*,
30 *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*,
PMI3715, and/or *gpmB*, preferably *secG*, *cyoC*, *pykF*, *flhB*,
dedA, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, and/or
gpmB.

According to certain embodiments of the first and/or second aspect of the invention the antimicrobial, e.g. antibiotic, drug is selected from quinolone antibiotics, preferably
5 fluoroquinolone antibiotics, and the presence of a mutation in the following genes is determined: parC, secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB, preferably secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB.

10

According to certain embodiments of the first and/or second aspect of the invention the antimicrobial, e.g. antibiotic, drug is selected from aminoglycoside antibiotics, and the presence of a mutation in the following genes is determined:
15 parC.

According to certain embodiments of the first and/or second aspect of the invention the antimicrobial, e.g. antibiotic, drug is selected from polyketide antibiotics, preferably tet-
20 racycline antibiotics, and the presence of a mutation in the following genes is determined: secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB.

According to certain embodiments of the first and/or second
25 aspect of the invention the antimicrobial, e.g. antibiotic, drug is selected from benzene derived/sulfonamide antibiotics, and the presence of a mutation in the following genes is determined: parC and/or fdoG, preferably fdoG.

30 According to certain embodiments, the antimicrobial drug is an antibiotic/antibiotic drug.

According to certain embodiments of the first and/or second aspect of the invention, determining the nucleic acid sequence information or the presence of a mutation comprises determining the presence of a single nucleotide at a single position in a gene. Thus the invention comprises methods wherein the presence of a single nucleotide polymorphism or mutation at a single nucleotide position is detected.

According to certain embodiments, the antibiotic drug in the methods of the present invention is selected from the group consisting of Amoxicillin/K Clavulanate (AUG), Ampicillin (AM), Aztreonam (AZT), Cefazolin (CFZ), Cefepime (CPE), Cefotaxime (CFT), Ceftazidime (CAZ), Ceftriaxone (CAX), Cefuroxime (CRM), Cephalotin (CF), Ciprofloxacin (CP), Ertapenem (ETP), Gentamicin (GM), Imipenem (IMP), Levofloxacin (LVX), Meropenem (MER), Piperacillin/Tazobactam (P/T), Ampicillin/Sulbactam (A/S), Tetracycline (TE), Tobramycin (TO), and Trimethoprim/Sulfamethoxazole (T/S).

The inventors have surprisingly found that mutations in certain genes are indicative not only for a resistance to one single antimicrobial, e.g. antibiotic, drug, but to groups containing several drugs.

According to certain embodiments of the first and/or second aspect of the invention, the gene is from Table 1 or Table 2, the antibiotic drug is selected from lactam antibiotics and a mutation in at least one of the following genes is detected with regard to reference genome NC_010554: parC, secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB, preferably secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB.

According to certain embodiments of the first and/or second aspect of the invention, the gene is from Table 1 or Table 2, the antibiotic drug is selected from quinolone antibiotics, preferably fluoroquinolone antibiotics, and a mutation in at least one of the following genes is detected with regard to reference genome NC_010554: parC, secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB, preferably secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB.

According to certain embodiments of the first and/or second aspect of the invention, the gene is from Table 1 or Table 2, the antibiotic drug is selected from aminoglycoside antibiotics and a mutation in at least one of the following genes is detected with regard to reference genome NC_010554: parC.

According to certain embodiments of the first and/or second aspect of the invention, the gene is from Table 1 or Table 2, the antibiotic drug is selected from polyketide antibiotics, preferably tetracycline antibiotics, and a mutation in at least one of the following genes is detected with regard to reference genome NC_010554: secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB.

According to certain embodiments of the first and/or second aspect of the invention, the gene is from Table 1 or Table 2, the antibiotic drug is selected from benzene derived/sulfonamide antibiotics and a mutation in at least one of the following genes is detected with regard to reference genome NC_010554: parC and/or fdoG, preferably fdoG.

For specific antimicrobial drugs, e.g. antibiotics, specific positions in the above genes can be determined where a high statistical significance is observed. The inventors found that, apart from the above genes indicative of a resistance against antibiotics, also single nucleotide polymorphisms (= SNP's) may have a high significance for the presence of a resistance against defined antibiotic drugs. The analysis of these polymorphisms on a nucleotide level may further improve and accelerate the determination of a drug resistance to antimicrobial drugs, e.g. antibiotics, in *Proteus*.

According to certain embodiments of the first and/or second aspect of the invention, the gene is from Table 1 or Table 2, the antibiotic drug is selected from lactam antibiotics and a mutation in at least one of the following nucleotide positions is detected with regard to reference genome NC_010554: 2562578, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 2454709, 3039125, 3221491, 3221494, 3422635, 4059624, 4059634, 4060202, 131835, preferably 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 2454709, 3039125, 3221491, 3221494, 3422635, 4059624, 4059634, 4060202, 131835.

According to certain embodiments of the first and/or second aspect of the invention, the gene is from Table 1 or Table 2, the antibiotic drug is selected from quinolone antibiotics, preferably fluoroquinolone antibiotics, and a mutation in at least one of the following nucleotide positions is detected with regard to reference genome NC_010554: 2562578, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 2454709, 3039125, 3221491, 3221494, 3422635, 4059624, 4059634, 4060202, 131835,

pref3741905, 131826, 1482764, 1771087, 1771119, 1918241,
1968294, 2238063, 2238072, 2238088, 2238090, 2454709,
3039125, 3221491, 3221494, 3422635, 4059624, 4059634,
4060202, 131835erably .

5

According to certain embodiments of the first and/or second
aspect of the invention, the gene is from Table 1 or Table 2,
the antibiotic drug is selected from aminoglycoside antibiot-
ics and a mutation in at least one of the following nucleo-
10 tide positions is detected with regard to reference genome
NC_010554: 2562578.

According to certain embodiments of the first and/or second
aspect of the invention, the gene is from Table 1 or Table 2,
15 the antibiotic drug is selected from polyketide antibiotics,
preferably tetracycline antibiotics, and a mutation in at
least one of the following nucleotide positions is detected
with regard to reference genome NC_010554: 3741905, 131826,
1482764, 1771087, 1771119, 1918241, 1968294, 2238063,
20 2238072, 2238088, 2238090, 2454709, 3039125, 3221491,
3221494, 3422635, 4059624, 4059634, 4060202, 131835.

According to certain embodiments of the first and/or second
aspect of the invention, the gene is from Table 1 or Table 2,
25 the antibiotic drug is selected from benzene de-
rived/sulfonamide antibiotics and a mutation in at least one
of the following nucleotide positions is detected with regard
to reference genome NC_010554: 2562578, 3422635, preferably
3422635.

30

According to certain embodiments of the first and/or second
aspect of the invention, the antibiotic drug is at least one
of CF, CFZ, CRM, CP, CAX, AM, A/S, LVX and AUG, and a muta-

tion in at least one of the following nucleotide positions is detected with regard to reference genome NC_010554: 2562578, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 2454709, 3039125, 5 3221491, 3221494, 3422635, 4059624, 4059634, 4060202, 131835, preferably 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 2454709, 3039125, 3221491, 3221494, 3422635, 4059624, 4059634, 4060202, 131835.

10

According to certain embodiments of the first and/or second aspect of the invention, the antibiotic drug is TE and a mutation in at least one of the following nucleotide positions is detected with regard to reference genome NC_010554:

15 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 2454709, 3039125, 3221491, 3221494, 3422635, 4059624, 4059634, 4060202, 131835.

According to certain embodiments of the first and/or second aspect of the invention, the antibiotic drug is CFT and a mutation in at least one of the following nucleotide positions is detected with regard to reference genome NC_010554:

20 2562578, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 3221491, 25 3221494, 4059624, 4059634, 4060202, 131835, preferably 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 3221491, 3221494, 4059624, 4059634, 4060202, 131835.

30 According to certain embodiments of the first and/or second aspect of the invention, the antibiotic drug is T/S and a mutation in at least one of the following nucleotide positions

is detected with regard to reference genome NC_010554:
2562578, 3422635, preferably 3422635.

According to certain embodiments of the first and/or second
5 aspect of the invention, the antibiotic drug is at least one
of GM and CPE and a mutation in at least one of the following
nucleotide positions is detected with regard to reference ge-
nome NC_010554: 2562578.

10 According to certain embodiments of the first and/or second
aspect of the invention, the resistance of a bacterial micro-
organism belonging to the species *Proteus* against 1, 2, 3, 4,
5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, 17, 18, 19, 20
or 21 antibiotic drugs is determined.

15

According to certain embodiments of the first and/or second
aspect of the invention, a detected mutation is a mutation
leading to an altered amino acid sequence in a polypeptide
derived from a respective gene in which the detected mutation
20 is located. According to this aspect, the detected mutation
thus leads to a truncated version of the polypeptide (wherein
a new stop codon is created by the mutation) or a mutated
version of the polypeptide having an amino acid exchange at
the respective position.

25

According to certain embodiments of the first and/or second
aspect of the invention, determining the nucleic acid se-
quence information or the presence of a mutation comprises
determining a partial sequence or an entire sequence of the
30 at least two genes.

According to certain embodiments of the first and/or second
aspect of the invention, determining the nucleic acid se-

quence information or the presence of a mutation comprises determining a partial or entire sequence of the genome of the Proteus species, wherein said partial or entire sequence of the genome comprises at least a partial sequence of said at least two genes.

According to certain embodiments of the first and/or second aspect of the invention, determining the nucleic acid sequence information or the presence of a mutation comprises using a next generation sequencing or high throughput sequencing method. According to preferred embodiments of the first and/or second aspect of the invention, a partial or entire genome sequence of the bacterial organism of Proteus species is determined by using a next generation sequencing or high throughput sequencing method.

In a further, third aspect, the present invention relates to a method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for bacterial microorganisms of Proteus species, comprising:

obtaining or providing a first data set of gene sequences of a plurality of clinical isolates of Proteus species;
providing a second data set of antimicrobial drug, e.g. antibiotic, resistance of the plurality of clinical isolates of Proteus species;
aligning the gene sequences of the first data set to at least one, preferably one, reference genome of Proteus, and/or assembling the gene sequence of the first data set, at least in part;
analyzing the gene sequences of the first data set for genetic variants to obtain a third data set of genetic variants;
correlating the third data set with the second data set and statistically analyzing the correlation; and

determining the genetic sites in the genome of *Proteus* associated with antimicrobial drug, e.g. antibiotic, resistance.

5 The different steps can be carried out as described with regard to the method of the first aspect of the present invention.

When referring to the second data set, wherein the second data set e.g. comprises, respectively is, a set of antimicrobial drug, e.g. antibiotic, resistances of a plurality of clinical isolates, this can, within the scope of the invention, also refer to a self-learning data base that, whenever a new sample is analyzed, can take this sample into the second data set and thus expand its data base. The second data set thus
10 does not have to be static and can be expanded, either by external input or by incorporating new data due to self-learning. This is, however, not restricted to the third aspect of the invention, but applies to other aspects of the invention that refer to a second data set, which does not
15 necessarily have to refer to antimicrobial drug resistance. The same applies, where applicable, to the first data set, e.g. in the third aspect.
20

According to certain embodiments, statistical analysis in the
25 present methods is carried out using Fisher's test with $p < 10^{-6}$, preferably $p < 10^{-9}$, particularly $p < 10^{-10}$.

The method of the third aspect of the present invention, as well as related methods, e.g. according to the 7th and 10th
30 aspect, can, according to certain embodiments, comprise correlating different genetic sites to each other, e.g. in at least two, three, four, five, six, seven, eight, nine or ten

genes. This way even higher statistical significance can be achieved.

According to certain embodiments of the method of the third
5 aspect and related methods - as above, the second data set is provided by culturing the clinical isolates of *Proteus* species on agar plates provided with antimicrobial drugs, e.g. antibiotics, at different concentrations and the second data is obtained by taking the minimal concentration of the plates
10 that inhibits growth of the respective *Proteus* species.

According to certain embodiments of the method of the third aspect and related methods, the antibiotic is at least one selected from the group of β -lactams, β -lactam inhibitors, quinolines and derivatives thereof, aminoglycosides,
15 tetracyclines, and folate synthesis inhibitors, preferably Amoxicillin/K Clavulanate, Ampicillin, Aztreonam, Cefazolin, Cefepime, Cefotaxime, Ceftazidime, Ceftriaxone, Cefuroxime, Cephalothin, Ciprofloxacin, Ertapenem, Gentamicin, Imipenem,
20 Levofloxacin, Meropenem, Piperacillin/Tazobactam, Ampicillin/Sulbactam, Tetracycline, Tobramycin, and Trimethoprim/Sulfamethoxazole.

According to certain embodiments of the method of the third
25 aspect and related methods, the gene sequences in the third data set are comprised in at least one gene from the group of genes consisting of *parC*, *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, *gpmB*, preferably *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939,
30 *fdoG*, PMI3715, *gpmB*, or from the genes listed in Table 5, preferably Table 5a.

According to certain embodiments of the method of the third aspect and related methods, the genetic variant has a point mutation, an insertion and or deletion of up to four bases, and/or a frameshift mutation, particularly a non-synonymous coding in YP_002152062.1.

A fourth aspect of the present invention relates to a method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for a bacterial microorganism belonging to the species *Proteus* comprising the steps of

- a) obtaining or providing a sample containing or suspected of containing the bacterial microorganism;
- b) determining the presence of a mutation in at least one gene of the bacterial microorganism as determined by the method of the third aspect of the invention;

wherein the presence of a mutation is indicative of a resistance to an antimicrobial drug, e.g. antibiotic, drug.

Steps a) and b) can herein be carried out as described with regard to the first aspect, as well as for the following aspects of the invention.

With this method, any mutations in the genome of *Proteus* species correlated with antimicrobial drug, e.g. antibiotic, resistance can be determined and a thorough antimicrobial drug, e.g. antibiotic, resistance profile can be established.

A simple read out concept for a diagnostic test as described in this aspect is shown schematically in Fig. 1.

According to Fig. 1, a sample 1, e.g. blood from a patient, is used for molecular testing 2, e.g. using next generation sequencing (NGS), and then a molecular fingerprint 3 is tak-

en, e.g. in case of NGS a sequence of selected genomic/plasmid regions or the whole genome is assembled. This is then compared to a reference library 4, i.e. selected sequences or the whole sequence are/is compared to one or more
5 reference sequences, and mutations (SNPs, sequence- gene additions/deletions, etc.) are correlated with susceptibility/reference profile of reference strains in the reference library. The reference library 4 herein contains many genomes and is different from a reference genome. Then the result 5
10 is reported comprising ID (pathogen identification), i.e. a list of all (pathogenic) species identified in the sample, and AST (antimicrobial susceptibility testing), i.e. a list including a susceptibility /resistance profile for all species listed

15

A fifth aspect of the present invention relates to a diagnostic method of determining an infection of a patient with Proteus species potentially resistant to antimicrobial drug treatment, which also can be described as method of determining an antimicrobial drug, e.g. antibiotic, resistant Proteus
20 infection in a patient, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing a bacterial microorganism belonging to the species Proteus from the patient;
- 25 b) determining the presence of at least one mutation in at least one gene of the bacterial microorganism belonging to the species Proteus as determined by the method of the third aspect of the present invention, wherein the presence of said at least one mutation is indicative of an antimicrobial drug,
30 e.g. antibiotic, resistant Proteus infection in said patient.

Again, steps a) and b) can herein be carried out as described with regard to the first aspect of the present invention.

According to this aspect, a Proteus infection in a patient can be determined using sequencing methods as well as a resistance to antimicrobial drugs, e.g. antibiotics, of the Proteus species be determined in a short amount of time compared to the conventional methods.

In a sixth aspect the present invention relates to a method of selecting a treatment of a patient suffering from an infection with a potentially resistant Proteus strain, e.g. an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing a bacterial microorganism belonging to the species Proteus from the patient;
- b) determining the presence of at least one mutation in at least one gene of the bacterial microorganism belonging to the species Proteus as determined by the method of the third aspect of the invention, wherein the presence of said at least one mutation is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and
- d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.

This method can be carried out similarly to the second aspect of the invention and enables a fast way to select a suitable treatment with antibiotics for any infection with an unknown Proteus species.

A seventh aspect of the present invention relates to a method of acquiring, respectively determining, an antimicrobial drug, e.g. antibiotic, resistance profile for a bacterial microorganism of *Proteus* species, comprising:

- 5 obtaining or providing a first data set of gene sequences of a clinical isolate of *Proteus* species;
providing a second data set of antimicrobial drug, e.g. antibiotic, resistance of a plurality of clinical isolates of *Proteus* species;
- 10 aligning the gene sequences of the first data set to at least one, preferably one, reference genome of *Proteus*, and/or assembling the gene sequence of the first data set, at least in part;
analyzing the gene sequences of the first data set for genetic variants to obtain a third data set of genetic variants of the first data set;
- 15 correlating the third data set with the second data set and statistically analyzing the correlation; and
determining the genetic sites in the genome of *Proteus* of the first data set associated with antimicrobial drug, e.g. antibiotic, resistance.
- 20

With this method, antimicrobial drug, e.g. antibiotic, resistances in an unknown isolate of *Proteus* can be determined.

25

According to certain embodiments, the reference genome of *Proteus* is NC_010554 as annotated at the NCBI. According to certain embodiments, statistical analysis in the present methods is carried out using Fisher's test with $p < 10^{-6}$, preferably $p < 10^{-9}$, particularly $p < 10^{-10}$. Also, according to certain embodiments, the method further comprises correlating different genetic sites to each other, e.g. in at

30

least two, three, four, five, six, seven, eight, nine or ten genes.

An eighth aspect of the present invention relates to a computer program product comprising computer executable instructions which, when executed, perform a method according to the third, fourth, fifth, sixth or seventh aspect of the present invention.

10 In certain embodiments the computer program product is one on which program commands or program codes of a computer program for executing said method are stored. According to certain embodiments the computer program product is a storage medium. The same applies to the computer program products of the aspects mentioned afterwards, i.e. the eleventh aspect of the present invention. As noted above, the computer program products of the present invention can be self-learning, e.g. with respect to the first and second data sets.

20 In order to obtain the best possible information from the highly complex genetic data and develop an optimum model for diagnostic and therapeutical uses as well as the methods of the present invention - which can be applied stably in clinical routine - a thorough in silico analysis can be necessary.

25 The proposed principle is based on a combination of different approaches, e.g. alignment with at least one, preferably more reference genomes and/or assembly of the genome and correlation of mutations found in every sample, e.g. from each patient, with all references and drugs, e.g. antibiotics, and

30 search for mutations which occur in several drug and several strains.

Using the above steps a list of mutations as well of genes is generated. These can be stored in databases and statistical models can be derived from the databases. The statistical models can be based on at least one or more mutations at
5 least one or more genes. Statistical models that can be trained can be combined from mutations and genes. Examples of algorithms that can produce such models are association Rules, Support Vector Machines, Decision Trees, Decision For-ests, Discriminant-Analysis, Cluster-Methods, and many more.

10

The goal of the training is to allow a reproducible, stand-ardized application during routine procedures.

For this, for example, a genome or parts of the genome of a
15 microorganism can be sequenced from a patient to be diag-nosed. Afterwards, core characteristics can be derived from the sequence data which can be used to predict resistance. These are the points in the database used for the final mod-el, i.e. at least one mutation or at least one gene, but also
20 combinations of mutations, etc.

The corresponding characteristics can be used as input for the statistical model and thus enable a prognosis for new pa-tients. Not only the information regarding all resistances of
25 all microorganisms, e.g. of Proteus species, against all drugs, e.g. antibiotics, can be integrated in a computer de-cision support tool, but also corresponding directives (e.g. EUCAST) so that only treatment proposals are made that are in line with the directives.

30

A ninth aspect of the present invention relates to the use of the computer program product according to the eighth aspect for acquiring an antimicrobial drug, e.g. antibiotic, re-

sistance profile for bacterial microorganisms of Proteus species or in a method of the third aspect of the invention.

In a tenth aspect a method of selecting a treatment of a patient having an infection with a bacterial microorganism of Proteus species, comprising:

5 obtaining or providing a first data set comprising a gene sequence of at least one clinical isolate of the microorganism from the patient;

10 providing a second data set of antimicrobial drug, e.g. antibiotic, resistance of a plurality of clinical isolates of the microorganism;

aligning the gene sequences of the first data set to at least one, preferably one, reference genome of the microorganism,

15 and/or assembling the gene sequence of the first data set, at least in part;

analyzing the gene sequences of the first data set for genetic variants to obtain a third data set of genetic variants of the first data set;

20 correlating the third data set with the second data set of antimicrobial drug, e.g. antibiotic, resistance of a plurality of clinical isolates of the microorganism and statistically analyzing the correlation;

determining the genetic sites in the genome of the clinical isolate of the microorganism of the first data set associated with antimicrobial drug, e.g. antibiotic, resistance; and

25 selecting a treatment of the patient with one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in the determination of the genetic sites associated with antimicrobial drug, e.g. antibiotic, resistance is disclosed.

30

Again, the steps can be carried out as similar steps before.

In this method, as well as similar ones, no aligning is necessary, as the unknown sample can be directly correlated, after the genome or genome sequences are produced, with the second data set and thus mutations and antimicrobial drug, e.g. antibiotic, resistances can be determined. The first data set can be assembled, for example, using known techniques. According to certain embodiments, statistical analysis in the present method is carried out using Fisher's test with $p < 10^{-6}$, preferably $p < 10^{-9}$, particularly $p < 10^{-10}$. Also, according to certain embodiments, the method further comprises correlating different genetic sites to each other.

An eleventh aspect of the present invention is directed to a computer program product comprising computer executable instructions which, when executed, perform a method according to the tenth aspect.

According to a twelfth aspect of the present invention, a diagnostic method of determining an infection of a patient with Proteus species potentially resistant to antimicrobial drug treatment, which can also be described as a method of determining an antimicrobial drug, e.g. antibiotic, resistant Proteus infection of a patient is disclosed, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;
- b) determining the presence of at least one mutation in at least two genes from the group of genes listed in Table 5, preferably Table 5a, wherein the presence of said at least two mutations is indicative of an antimicrobial drug, e.g. antibiotic, resistant Proteus infection in said patient.

A thirteenth aspect of the invention discloses a method of selecting a treatment of a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection, comprising the steps of:

- 5 a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
- b) determining the presence of at least one mutation in at least two genes from the group of genes listed in Table 5, preferably Table 5a, wherein the presence of said at least
10 two mutations is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and
- d) selecting one or more antimicrobial, e.g. antibiotic,
15 drugs different from the ones identified in step c) and being suitable for the treatment of a *Proteus* infection.

Again, the steps can be carried out as in similar methods before, e.g. as in the first and second aspect of the invention.
20 In the twelfth and thirteenth aspect of the invention, all classes of antibiotics considered in the present method are covered.

Herein, the genes in Table 5 are the following:

- 25 parC, secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, gpmB, dnaK, nhaA, ribF, ileS, carA, hyb0, hybA, hybB, hybD, cpdB, yajC, secD, secF, dxs, cyoE, cyoD, cyoB, tig, acrA, priC, dnaX, PMI0140, recR, dksA, pyrG, eno, epd, fbaA, PMI0341, nqrC, rimM, trmD, rplS, PMI0392,
30 lipA, lipB, PMI3693, ompF, PMI3449, msbB, nagC, gyrB, PMI2908, rpoC, PMI2124, PMI0936, mgtE, PMI1294, dmsA, gabD, PMI1896, PMI2380, hpmA, cscA, PMI2922, PMI1221, PMI0910, sucC, caiA, PMI3369, hemA, holC, gppA, PMI2178, gpsA, argI, PMI2961, PMI2783, kdsC, dacA, galK, emrB, fabF, pheT, cheB,

nuoL, nuoJ, fixC, PMI2772, kefB, pstS, frdB, rpoN, tata, yfbB, PMI2201, PMI0191, prc, fliK, nuoG, nuoC, atpA, and ilvB.

5 Herein, the genes in Table 5a are the following:
 secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939,
 fdoG, PMI3715, gpmB, dnaK, nhaA, ribF, ileS, carA, hyb0,
 hybA, hybB, hybD, cpdB, yajC, secD, secF, dxs, cyoE, cyoD,
 cyoB, tig, priC, dnaX, PMI0140, recR, dksA, pyrG, eno, epd,
 10 fbaA, PMI0341, nqrC, rimM, trmD, rplS, PMI0392, lipA, lipB,
 PMI3693, ompF, PMI3449, msbB, nagC, PMI2908, rpoC, PMI2124,
 PMI0936, mgtE, PMI1294, dmsA, gabD, PMI1896, PMI2380, hpmA,
 cscA, PMI2922, PMI1221, PMI0910, sucC, caiA, PMI3369, hemA,
 holC, gppA, PMI2178, gpsA, argI, PMI2961, PMI2783, kdsC,
 15 dacA, galK, emrB, fabF, pheT, cheB, nuoL, nuoJ, fixC,
 PMI2772, kefB, pstS, frdB, rpoN, tata, yfbB, PMI2201,
 PMI0191, prc, fliK, nuoG, nuoC, atpA, and ilvB.

According to certain embodiments, mutations in at least two,
 20 three, four, five, six, seven, eight, nine or ten genes are
 determined in any of the methods of the present invention,
 e.g. in at least two genes or in at least three genes. In-
 stead of testing only single genes or mutants, a combination
 of several variant positions can improve the prediction accu-
 25 racy and further reduce false positive findings that are in-
 fluenced by other factors. Therefore, it is in particular
 preferred to determine the presence of a mutation in 2, 3, 4,
 5, 6, 7, 8 or 9 (or more) genes selected from Table 5, pref-
 erably Table 5a.

30

Table 5: List of genes

parC	secG	cyoC	pykF	flhB
dedA	crr	murF	gmhB	purH
PMI2939	fdoG	PMI3715	gpmB	dnaK
nhaA	ribF	ileS	carA	hyb0
hybA	hybB	hybD	cpdB	yajC
secD	secF	dxs	cyoE	cyoD

cyoB	tig	acrA	priC	dnaX
PMI0140	recR	dksA	pyrG	eno
epd	fbaA	PMI0341	nqrC	rimM
trmD	rplS	PMI0392	lipA	lipB
PMI3693	ompF	PMI3449	msbB	nagC
gyrB	PMI2908	rpoC	PMI2124	PMI0936
mgte	PMI1294	dmsA	gabD	PMI1896
PMI2380	hpmA	cscA	PMI2922	PMI1221
PMI0910	sucC	caiA	PMI3369	hemA
holC	gppA	PMI2178	gpsA	argI
PMI2961	PMI2783	kdsC	dacA	galK
emrB	fabF	pheT	cheB	nuoL
nuoJ	fixC	PMI2772	kefB	pstS
frdB	rpoN	tatA	yfbB	PMI2201
PMI0191	prc	fliK	nuoG	nuoC
atpA	ilvB			

Table 5a: List of genes

ilvB	secG	cyoC	pykF	flhB
dedA	crr	murF	gmhB	purH
PMI2939	fdoG	PMI3715	gpmB	dnaK
nhaA	ribF	ileS	carA	hyb0
hybA	hybB	hybD	cpdB	yajC
secD	secF	dxs	cyoE	cyoD
cyoB	tig	atpA	priC	dnaX
PMI0140	recR	dksA	pyrG	eno
epd	fbaA	PMI0341	nqrC	rimM
trmD	rplS	PMI0392	lipA	lipB
PMI3693	ompF	PMI3449	msbB	nagC
nuoC	PMI2908	rpoC	PMI2124	PMI0936
mgte	PMI1294	dmsA	gabD	PMI1896
PMI2380	hpmA	cscA	PMI2922	PMI1221
PMI0910	sucC	caiA	PMI3369	hemA
holC	gppA	PMI2178	gpsA	argI
PMI2961	PMI2783	kdsC	dacA	galK
emrB	fabF	pheT	cheB	nuoL
nuoJ	fixC	PMI2772	kefB	pstS
frdB	rpoN	tatA	yfbB	PMI2201
PMI0191	prc	fliK	nuoG	

Further, according to certain embodiments, the reference genome of Proteus is again NC_010554 as annotated at the NCBI. According to certain embodiments, statistical analysis in the present methods is carried out using Fisher's test with $p < 10^{-6}$, preferably $p < 10^{-9}$, particularly $p < 10^{-10}$. Also, according to certain embodiments, the method further comprises

correlating different genetic sites to each other. Also the other aspects of the embodiments of the first and second aspect of the invention apply.

Table 6: List for lactam antibiotics

gene name	POS	antibiotic	gene	p-value (FDR)	genbank accession number	protein accession number
parC	2562578	CF; T/S; CP; CFT; GM; CFZ; CRM; CAX; CPE; AM; A/S; LVX; AUG		4, 65979E-71	YP_002152062.1	
PMI3693	4032998	CF; TE; CFT; CFZ; CRM; CAX; P/T; AM; A/S; AUG		2, 1905E-34	YP_002153368.1	
ompF	849533	CF; TE; CFT; CFZ; CRM; CAX; P/T; AM; A/S; AUG		1, 44267E-30	YP_002150530.1	
PMI3449	3777669	CF; CFT; CFZ; CRM; CAX; CPE; AM; A/S; AUG		9, 11622E-26	YP_002153133.1	
msbB	1214898	CF; CFT; CFZ; CRM; CAX; CPE; AM; A/S; AUG		5, 99293E-22	YP_002150887.1	
nagC	521806	CF; CFT; CFZ; CRM; CAX; CPE; AM; A/S; AUG		1, 38786E-20	YP_002150224.1	
gyrB	3450194	CF; CFT; CFZ; CRM; CAX; P/T; AM; A/S; AUG		1, 177E-19	YP_002152825.1	
secG	3741905	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		5, 11728E-63	YP_002153099.1	
cyoC	131826	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002149890.1	
pykF	1482764	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151136.1	
flhB	1771087	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151391.1	
flhB	1771119	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151391.1	
dedA	1918241	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151518.1	
crr	1968294	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151557.1	
murF	2238063	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151793.1	
murF	2238072	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151793.1	
murF	2238088	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151793.1	
murF	2238090	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002151793.1	
PMI2939	3221491	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002152640.1	
PMI2939	3221494	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG		7, 38724E-63	YP_002152640.1	

PMI3715	4059624	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002153390.1
PMI3715	4059634	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002153390.1
gpmB	4060202	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002153391.1
cyoC	131835	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	8,38542E-63	YP_002149890.1

FDR: determined according to FDR (Benjamini Hochberg) method (Benjamini Hochberg, 1995)

Table 6a: List for lactam antibiotics

gene name	POS	antibiotic	p-value (FDR)	genbank accession number	protein accession number
PMI3693	4032998	CF;TE;CFT;CFZ;CRM;CAX;P/T;AM;A/S;AUG	2,1905E-34	YP_002153368.1	
ompF	849533	CF;TE;CFT;CFZ;CRM;CAX;P/T;AM;A/S;AUG	1,44267E-30	YP_002150530.1	
PMI3449	3777669	CF;CFT;CFZ;CRM;CAX;CPE;AM;A/S;AUG	9,11622E-26	YP_002153133.1	
msbB	1214898	CF;CFT;CFZ;CRM;CAX;CPE;AM;A/S;AUG	5,99293E-22	YP_002150887.1	
nagC	521806	CF;CFT;CFZ;CRM;CAX;CPE;AM;A/S;AUG	1,38786E-20	YP_002150224.1	
secG	3741905	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	5,11728E-63	YP_002153099.1	
cyoC	131826	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002149890.1	
pykF	1482764	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151136.1	
flhB	1771087	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151391.1	
flhB	1771119	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151391.1	
dedA	1918241	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151518.1	
crr	1968294	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151557.1	
murF	2238063	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151793.1	
murF	2238072	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151793.1	
murF	2238088	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151793.1	

murF	2238090	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151793.1
PMI2939	3221491	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002152640.1
PMI2939	3221494	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002152640.1
PMI3715	4059624	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002153390.1
PMI3715	4059634	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002153390.1
gpmb	4060202	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002153391.1
cyoC	131835	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	8,38542E-63	YP_002149890.1

According to certain embodiments of the method of the twelfth and/or thirteenth aspect of the present invention, as well as also of the eighteenth aspect of the present invention, the antimicrobial drug is an antibiotic. According to certain em-
5 bodiments, the antibiotic is a lactam antibiotic and a mutation in at least one of the genes listed in Table 6, preferably Table 6a, is detected, or a mutation in at least one of the positions (denoted POS in the tables) listed in Table 6, preferably Table 6a.

10

According to certain embodiments of the method of the twelfth and/or thirteenth aspect of the present invention, as well as also of the eighteenth aspect of the present invention, the antibiotic is at least one of CF, CFT, CFZ, CRM, CAX, AM, A/S
15 and AUG and a mutation in at least one of the genes of parC, PMI3693, ompF, PMI3449, msbB, nagC, gyrB, secG, cyoC, pykF, flhB, dedA, crr, murF, PMI2939, PMI3715, gpmB, preferably PMI3693, ompF, PMI3449, msbB, nagC, secG, cyoC, pykF, flhB, dedA, crr, murF, PMI2939, PMI3715, gpmB, is detected, or a
20 mutation in at least one of the positions of 2562578, 4032998, 849533, 3777669, 1214898, 521806, 3450194, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 3221491, 3221494, 4059624, 4059634, 4060202, 131835, preferably 4032998, 849533,
25 3777669, 1214898, 521806, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 3221491, 3221494, 4059624, 4059634, 4060202, 131835.

30

According to certain embodiments of the method of the twelfth and/or thirteenth aspect of the present invention, as well as also of the eighteenth aspect of the present invention, the antibiotic is CPE and a mutation in at least one of the genes of parC, PMI3449, msbB, nagC, preferably PMI3449, msbB, nagC,

is detected, or a mutation in at least one of the positions of 2562578, 3777669, 1214898, 521806, preferably 3777669, 1214898, 521806.

5 According to certain embodiments of the method of the twelfth and/or thirteenth aspect of the present invention, as well as also of the eighteenth aspect of the present invention, the antibiotic is P/T and a mutation in at least one of the genes of PMI3693, ompF, gyrB, preferably PMI3693, ompF, is detected,
10 ed, or a mutation in at least one of the positions of 4032998, 849533, 3450194, preferably 4032998, 849533.

According to certain embodiments of the method of the twelfth and/or thirteenth aspect of the present invention, as well as
15 also of the eighteenth aspect of the present invention, the antibiotic is a quinolone antibiotic and a mutation in at least one of the genes listed in Table 7, preferably Table 7a, is detected, or a mutation in at least one of the positions (denoted POS in the tables) listed in Table 7, preferably
20 bly Table 7a.

According to certain embodiments of the method of the twelfth and/or thirteenth aspect of the present invention, as well as also of the eighteenth aspect of the present invention, the
25 antibiotic is at least one of CP and LVX and a mutation in at least one of the genes of parC, secG, cyoC, pykF, flhB, dedA, crr, murF, PMI2939, PMI3715, gpmB, gmhB, purH, fdoG, preferably secG, cyoC, pykF, flhB, dedA, crr, murF, PMI2939, PMI3715, gpmB, gmhB, purH, fdoG, is detected, or a mutation
30 in at least one of the positions of 2562578, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294, 2238063, 2238072, 2238088, 2238090, 3221491, 3221494, 4059624, 4059634, 4060202, 2454709, 3039125, 3422635, 131835, prefera-

bly 3741905, 131826, 1482764, 1771087, 1771119, 1918241,
1968294, 2238063, 2238072, 2238088, 2238090, 3221491,
3221494, 4059624, 4059634, 4060202, 2454709, 3039125,
3422635, 131835.

5

According to certain embodiments of the method of the twelfth
and/or thirteenth aspect of the present invention, as well as
also of the eighteenth aspect of the present invention, the
antibiotic is an aminoglycoside antibiotic and a mutation in
10 at least one of the genes listed in Table 8 is detected, or a
mutation in at least one of the positions (denoted POS in the
tables) listed in Table 8.

Table 7: List for quinolone antibiotics

gene name	POS	antibiotic	p-value (FDR)	genbank accession number	protein
parC	2562578	CF; T/S; CP; CFT; GM; CFZ; CRM; CAX; CPE; AM; A/S; LVX; AUG	4, 65979E-71	YP_002152062.1	
secG	3741905	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	5, 11728E-63	YP_002153099.1	
cyoC	131826	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002149890.1	
pykF	1482764	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151136.1	
flhB	1771087	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151391.1	
flhB	1771119	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151391.1	
dedA	1918241	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151518.1	
crr	1968294	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151557.1	
murF	2238063	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151793.1	
murF	2238072	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151793.1	
murF	2238088	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151793.1	
murF	2238090	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151793.1	
PMI2939	3221491	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002152640.1	
PMI2939	3221494	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002152640.1	
PMI3715	4059624	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002153390.1	
PMI3715	4059634	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002153390.1	
gpmB	4060202	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002153391.1	
gmhB	2454709	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002151976.1	
purH	3039125	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002152469.1	
fdoG	3422635	CF; T/S; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP_002152801.1	

gene name	POS	antibiotic	p-value (FDR)	genbank accession number	protein
cyoC	131835	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	8,38542E-63	YP_002149890.1	
secG	3741905	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	5,11728E-63	YP_002153099.1	
cyoC	131826	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002149890.1	
pykF	1482764	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151136.1	
flhB	1771087	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151391.1	
flhB	1771119	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151391.1	
dedA	1918241	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151518.1	
crr	1968294	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151557.1	
murF	2238063	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151793.1	
murF	2238072	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151793.1	
murF	2238088	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151793.1	
murF	2238090	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002151793.1	
PMI2939	3221491	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002152640.1	
PMI2939	3221494	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002152640.1	
PMI3715	4059624	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002153390.1	
PMI3715	4059634	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002153390.1	
gpmB	4060202	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7,38724E-63	YP_002153391.1	

5 Table 7a: List for quinolone antibiotics

gmhB	2454709	CF;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002151976.1
purH	3039125	CF;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002152469.1
fdoG	3422635	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP_002152801.1
cyoC	131835	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	8,38542E-63	YP_002149890.1

Table 8: List of aminoglycoside antibiotics

gene name	POS	antibiotic	p-value (FDR)	genbank protein accession number
PMI2908	3189475	TO;GM	1,3778E-18	YP_002152609.1
rpoC	3053893	T/S;LVX;CP;TO;GM	9,3802E-18	YP_002152485.1
PMI2124	2299533	T/S;CP;GM;A/S;TO;LVX	2,5842E-17	YP_002151843.1
PMI0936	1013893	T/S;LVX;CP;TO;GM	3,7067E-17	YP_002150693.1
mgte	2281052	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	1,6949E-16	YP_002151828.1
PMI1294	1367519	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	1,9698E-16	YP_002151025.1
dmsA	1823348	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	2,0354E-16	YP_002151436.1
gabD	3708304	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	2,1492E-16	YP_002153067.1
PMI1896	2041811	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	2,3262E-16	YP_002151623.1
PMI2380	2603984	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	2,4203E-16	YP_002152098.1
hpmA	2218536	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	2,5198E-16	YP_002151778.1
cscA	2376673	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	2,5198E-16	YP_002151908.1
PMI2922	3206198	CF;T/S;CP;GM;CFZ;TO; AM;A/S;LVX;AUG	2,5198E-16	YP_002152623.1
PMI1221	1290778	T/S;A/S;TO;AM;GM	3,4286E-16	YP_002150953.1
PMI0910	994331	T/S;CP;TO;GM	3,4366E-16	YP_002150667.1

According to certain embodiments of the method of the twelfth and/or thirteenth aspect of the present invention, as well as also of the eighteenth aspect of the present invention, the antibiotic is at least one of GM and TO and a mutation in at least one of the genes of PMI2908, rpoC, PMI2124, PMI0936, mgte, PMI1294, dmsA, gabD, PMI1896, PMI2380, hpmA, cscA, PMI2922, PMI1221, PMI0910 is detected, or a mutation in at least one of the positions of 3189475, 3053893, 2299533,

1013893, 2281052, 1367519, 1823348, 3708304, 2041811,
2603984, 2218536, 2376673, 3206198, 1290778, 994331.

According to certain embodiments of the method of the twelfth
5 and/or thirteenth aspect of the present invention, as well as
also of the eighteenth aspect of the present invention, the
antibiotic is an polyketide antibiotic and a mutation in at
least one of the genes listed in Table 9 is detected, or a
mutation in at least one of the positions (denoted POS in the
10 tables) listed in Table 9.

According to certain embodiments of the method of the twelfth
and/or thirteenth aspect of the present invention, as well as
also of the eighteenth aspect of the present invention, the
15 antibiotic is TE and a mutation in at least one of the genes
of secG, cyoC, pykF, flhB, dedA, crr, murF, PMI2939, PMI3715,
gpmB, gmhB, purH, fdoG is detected, or a mutation in at least
one of the positions of 3741905, 131826, 1482764, 1771087,
1771119, 1918241, 1968294, 2238063, 2238072, 2238088,
20 2238090, 3221491, 3221494, 4059624, 4059634, 4060202,
2454709, 3039125, 3422635, 131835.

According to certain embodiments of the method of the seven-
teenth and/or eighteenth aspect of the present invention, the
25 antibiotic is T/S and a mutation in at least one of the genes
listed in Table 10, preferably Table 10a, is detected, or a
mutation in at least one of the positions (denoted POS in the
tables) listed in Table 10, preferably Table 10a.

Table 9: List of polyketides, preferably tetracycline

gene name	POS	antibiotic	p-value (FDR)	genbank accession number	protein accession number
secG	3741905	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	5, 11728E-63	YP 002153099.1	
cyoC	131826	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002149890.1	
pykF	1482764	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151136.1	
flhB	1771087	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151391.1	
flhB	1771119	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151391.1	
dedA	1918241	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151518.1	
crr	1968294	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151557.1	
murF	2238063	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151793.1	
murF	2238072	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151793.1	
murF	2238088	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151793.1	
murF	2238090	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151793.1	
PMI2939	3221491	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002152640.1	
PMI2939	3221494	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002152640.1	
PMI3715	4059624	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002153390.1	
PMI3715	4059634	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002153390.1	
gpmB	4060202	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002153391.1	
gmhB	2454709	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002151976.1	
purH	3039125	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002152469.1	
fdoG	3422635	CF; T/S; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	7, 38724E-63	YP 002152801.1	
cyoC	131835	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	8, 38542E-63	YP 002149890.1	

Table 10: List of others antibiotics ((benzene derived)/sulfonamide)

gene name	POS	antibiotic	p-value (FDR)	genbank accession number	protein accession number
parC	2562578	CF;T/S;CP;CFT;GM;CFZ;CRM;CAX;CPE;AM;A/S;LVX;AUG	4,65979E-71	YP 002152062.1	
fdoG	3422635	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP 002152801.1	
dnaK	19958	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002149796.1	
nhaA	21872	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002149798.1	
fabF	952747	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002150620.1	
pheT	1104454	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002150789.1	
cheB	1773746	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002151394.1	
nuoL	1876979	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002151482.1	
nuoJ	1879024	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002151484.1	
fixC	2898978	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152352.1	
PMI2772	3042468	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152473.1	
kefB	3076139	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152506.1	
pstS	3174532	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152594.1	
frdB	3918248	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002153262.1	
fixC	2898937	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,73077E-62	YP 002152352.1	

Table 10a: List of others antibiotics ((benzene derived)/sulfonamide)

gene name	POS	antibiotic	p-value (FDR)	genbank accession number	protein accession number
fdoG	3422635	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	7,38724E-63	YP 002152801.1	

dnaK	19958	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002149796.1
nhaA	21872	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002149798.1
fabF	952747	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002150620.1
pheT	1104454	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002150789.1
cheB	1773746	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002151394.1
nuoL	1876979	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002151482.1
nuoJ	1879024	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002151484.1
fixC	2898978	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152352.1
PMI2772	3042468	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152473.1
kefB	3076139	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152506.1
pstS	3174532	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002152594.1
frdB	3918248	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,04565E-62	YP 002153262.1
fixC	2898937	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	1,73077E-62	YP 002152352.1

A fourteenth aspect of the present invention is directed to a diagnostic method of determining an infection of a patient with *Proteus* species potentially resistant to antimicrobial drug treatment, which can also be described as method of determining an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection of a patient, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
- b) determining the presence of at least one mutation in at least one gene from the group of genes consisting of *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, *gpmB*, particularly *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *purH*, PMI2939, *fdoG*, PMI3715, *gpmB*, wherein the presence of said at least one mutation is indicative of an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection in said patient.

A fifteenth aspect of the present invention is directed to a method of selecting a treatment of a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
- b) determining the presence of at least one mutation in at least one gene from the group of genes consisting of *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, *gpmB*, particularly *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *purH*, PMI2939, *fdoG*, PMI3715, *gpmB*, wherein the presence of said at least one mutation is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and

d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.

5 Again, in the fourteenth and the fifteenth aspect the steps correspond to those in the first or second aspect, although only a mutation in at least one gene is determined.

A sixteenth aspect of the present invention is directed to a
10 method of treating a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;
- 15 b) determining the presence of at least one mutation in at least one gene from the group of genes consisting of secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, gpmB, particularly secG, cyoC, pykF, flhB, dedA, crr, purH, PMI2939, fdoG, PMI3715, gpmB, wherein the presence
20 of said at least one mutation is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs;
- d) selecting one or more antimicrobial, e.g. antibiotic,
25 drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection; and
- e) treating the patient with said one or more antimicrobial, e.g. antibiotic, drugs.

30 A seventeenth aspect of the present invention is directed to a method of treating a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
- b) determining the presence of at least one mutation in at least two genes from the group of genes consisting of *parC*,
5 *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, *gpmB*, preferably *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, PMI2939, *fdoG*, PMI3715, *gpmB*, wherein the presence of said at least two mutations is indicative of a resistance to one or more antimicrobial, e.g. antibiotic,
10 drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs;
- d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being
15 suitable for the treatment of a *Proteus* infection; and
- e) treating the patient with said one or more antimicrobial, e.g. antibiotic, drugs.

An eighteenth aspect of the present invention is directed to
20 a method of treating a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant *Proteus* infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
- 25 b) determining the presence of at least one mutation in at least two genes from the group of genes listed in Table 5, preferably Table 5a, wherein the presence of said at least two mutations is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- 30 c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs;

- d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection; and
- e) treating the patient with said one or more antimicrobial, e.g. antibiotic, drugs.

A nineteenth aspect of the present invention is directed to method of treating a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;
- b) determining the presence of at least one mutation in at least one gene from the group of genes listed in Table 11, preferably Table 11a, preferably from the group of genes listed in Table 12, wherein the presence of said at least one mutation is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs;
- d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection; and
- e) treating the patient with said one or more antimicrobial, e.g. antibiotic, drugs.

Also in the sixteenth to nineteenth aspect of the invention, steps a) to d) are analogous to the steps in the method of the second aspect of the present invention. Step e) can be sufficiently carried out without being restricted and can be done e.g. non-invasively.

A twentieth aspect of the present invention is directed to a diagnostic method of determining an infection of a patient with Proteus species potentially resistant to antimicrobial drug treatment, which can also be described as method of determining an antimicrobial drug, e.g. antibiotic, resistant Proteus infection of a patient, comprising the steps of:

a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;

b) determining the presence of at least one mutation in at

least one gene from the group of genes listed in Table 11, preferably Table 11a, preferably from the group of genes listed in Table 12, wherein the presence of said at least one mutation is indicative of an antimicrobial drug, e.g. antibiotic, resistant Proteus infection in said patient.

A twenty-first aspect of the present invention is directed to a method of selecting a treatment of a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:

a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;

b) determining the presence of at least one mutation in at least one gene from the group of genes listed in Table 11, preferably Table 11a, preferably from the group of genes

listed in Table 12, wherein the presence of said at least one mutation is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;

c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and

d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.

Again, in the twentieth and the twenty-first aspect the steps correspond to those in the first or second aspect, although only a mutation in at least one gene is determined.

5 Table 11: List of genes

ilvB	secG	cyoC	pykF	flhB
dedA	crr	murF	gmhB	purH
PMI2939	fdoG	PMI3715	gpmB	dnaK
nhaA	ribF	ileS	carA	hyb0
hybA	hybB	hybD	cpdB	yajC
secD	secF	dxs	cyoE	cyoD
cyoB	tig	acrA	priC	dnaX
PMI0140	recR	dksA	pyrG	eno
epd	fbaA	PMI0341	nqrC	rimM
trmD	rplS	PMI0392	lipA	lipB
PMI3693	atpA	PMI3449	msbB	nagC
nuoC	PMI2908	rpoC	PMI2124	PMI0936
mgtE	PMI1294	dmsA	gabD	PMI1896
PMI2380	hpmA	cscA	PMI2922	PMI1221
PMI0910	sucC	caiA	PMI3369	hemA
holC	gppA	PMI2178	gpsA	argI
PMI2961	PMI2783	kdsC	dacA	galK
emrB	fabF	pheT	cheB	nuoL
nuoJ	fixC	PMI2772	kefB	pstS
frdB	rpoN	tataA	yfbB	PMI2201
PMI0191	prc	fliK	nuoG	

Table 11a: List of genes

ilvB	secG	cyoC	pykF	flhB
dedA	crr	murF	gmhB	purH
PMI2939	fdoG	PMI3715	gpmB	dnaK
nhaA	ribF	ileS	carA	hyb0
hybA	hybB	hybD	cpdB	yajC
secD	secF	dxs	cyoE	cyoD
cyoB	tig	nuoG	priC	dnaX
PMI0140	recR	dksA	pyrG	eno
epd	fbaA	PMI0341	nqrC	rimM

trmD	rplS	PMI0392	lipA	lipB
PMI3693	atpA	PMI3449	msbB	nagC
nuoC	PMI2908	rpoC	PMI2124	PMI0936
mgteE	PMI1294	dmsA	gabD	PMI1896
PMI2380	hpmA	cscA	PMI2922	PMI1221
PMI0910	sucC	caiA	PMI3369	hemA
holC	gppA	PMI2178	gpsA	argI
PMI2961	PMI2783	kdsC	dacA	galK
emrB	fabF	pheT	cheB	nuoL
nuoJ	fixC	PMI2772	kefB	pstS
frdB	rpoN	tataA	yfbB	PMI2201
PMI0191	prc	fliK		

Table 12: List of genes

ilvB	secG	cyoC	pykF	flhB
dedA	crr	fliK	PMI0191	purH
PMI2939	fdoG	PMI3715	gpmB	PMI2201
nhaA	ribF	yfbB	frdB	hyb0
hybA	hybB	hybD	cpdB	kefB
PMI2772	fixC	dxs	cyoE	cyoD
cyoB	nuoJ	nuoL	priC	dnaX
PMI0140	cheB	pheT	kdsC	PMI2783
epd	fbaA	PMI0341	nqrC	rimM
PMI2961	argI	PMI0392	lipA	lipB
PMI3693	PMI2178	PMI3449	holC	nagC
nuoC	PMI2908	PMI3369	PMI2124	PMI0936
caiA	PMI1294	dmsA	gabD	PMI1896
PMI2380	hpmA	cscA	PMI2922	PMI1221
PMI0910	sucC			

According to a twenty-second aspect of the present invention,
5 a diagnostic method of determining an infection of a patient
with *Proteus* species potentially resistant to antimicrobial
drug treatment, which can also be described as a method of
determining an antimicrobial drug, e.g. antibiotic, resistant

Proteus infection of a patient is disclosed, comprising the steps of:

- a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;
- 5 b) determining the presence of at least one mutation in at least two genes from the group of genes listed in Table 13, preferably Table 13a, wherein the presence of said at least two mutations is indicative of an antimicrobial drug, e.g. antibiotic, resistant Proteus infection in said patient.

10

A twenty-third aspect of the invention discloses a method of selecting a treatment of a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:

- 15 a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;
- b) determining the presence of at least one mutation in at least two genes from the group of genes listed in Table 13, preferably Table 13a, wherein the presence of said at least
- 20 two mutations is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
- c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and
- d) selecting one or more antimicrobial, e.g. antibiotic,
- 25 drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.

Again, the steps can be carried out as in similar methods before, e.g. as in the first and second aspect of the invention. In the twenty-second and twenty-third aspect of the invention, as well as the twenty-fourth aspect, all classes of antibiotics considered in the present method are covered, the reference genome is again NC_010554 as annotated at the NCBI,

30

and the statistical analysis is carried out using Fisher's test with $p < 10^{-6}$, preferably $p < 10^{-9}$, particularly $p < 10^{-10}$.

- 5 A twenty-fourth aspect of the present invention is directed to a method of treating a patient suffering from an antimicrobial drug, e.g. antibiotic, resistant Proteus infection, comprising the steps of:
- 10 a) obtaining or providing a sample containing or suspected of containing at least one Proteus species from the patient;
 - b) determining the presence of at least one mutation in at least two genes from the group of genes listed in Table 13, preferably Table 13a, wherein the presence of said at least two mutations is indicative of a resistance to one or more
15 antimicrobial, e.g. antibiotic, drugs;
 - c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs;
 - d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being
20 suitable for the treatment of a Proteus infection; and
 - e) treating the patient with said one or more antimicrobial, e.g. antibiotic, drugs.

Also in the twenty-fourth aspect of the invention, steps a) to d) are analogous to the steps in the method of the second
25 aspect of the present invention. Step e) can be sufficiently carried out without being restricted and can be done e.g. non-invasively.

30 The genes in Table 13, as well as Table 13a, thereby cover still p-values with very high probability, with the last gene in Table 13 and the corresponding gene in Table 13a still having a p-value of $1,06789 \text{ E}^{-62}$, with the same n and α as before.

Table 13: List of genes

parC	secG	cyoC	pykF	flhB	dedA	crr	murF
gmhB	purH	PMI2939	fdoG	PMI3715	gpmB	dnaK	nhaA
ribF	ileS	carA	hyb0	hybA	hybB	hybD	cpdB
yajC	secD	secF	dxs	cyoE	cyoD	cyoB	tig
acrA	priC	dnaX	PMI0140	recR	dksA	dksA	pyrG
eno	epd	fbaA	PMI0341	nqrC	rimM	trmD	rpls
PMI0392	lipA	lipB	corC	miaB	ubiF	gltA	sdhC
sdhA	sdhB	sucA	sucB	sucC	PMI0580	tolQ	tolB
pal	PMI0586	gpmA	PMI0648	clpA	serS	pflA	pflB
rpsA	aspC	ompF	asnC	pncB	rlmL	ompA	PMI0855
PMI0856	rpmF	plsX	fabH	fabG	fabF	lolC	PMI1014
proQ	thrS	rpmI	rplT	pheS	pheT	prsA	ipk
prfA	hemK	znuA	pykA	fumC	nth	rnb	tyrS
gapA	pgsA	uvrC	guaB	xseA	dapA	upp	purM
PMI1580	fliZ	fliA	fliG	fliK	fliL	fliN	flgB
flhA	cheY	cheB	cheR	PMI1665	PMI1666	motB	gyrA
nrdB	yfbB	nuoM	nuoL	nuoK	nuoJ	nuoI	nuoH
nuoG	nuoF	nuoE	nuoC	nuoA	PMI1763	PMI1767	ackA
purF	cvpA	fabB	ptsI	PMI1846	iscS	iscR	acnB
lpdA	aceF	ace	lpxC	ftsZ	ftsA	ftsQ	PMI2068
murC	mraZ	fold	ppiB	PMI2252	fabZ	lpxD	yaeT
ecfE	uppS	pyrH	tsf	rpsB	PMI2361	dnaG	rpoD
deoC	PMI2417	hyfD	hyfC	hyfB	hyfA	PMI2531	groL
groS	fixC	caiT	PMI2717	PMI2719	PMI2720	PMI2721	PMI2722
potA	PMI2745	uvrA	ssb	lexA	dgkA	plsB	PMI2770
PMI2772	rpoC	rpoB	rplL	rplJ	rplA	rplK	nusG
secE	fusA	rpsL	PMI2796	slyD	PMI2804	kefB	kefG
gmK	spoT	envZ	pstS	glpG	glpD	PMI2937	PMI2938
PMI2940	PMI2941	prlC	damX	gidA	atpI	atpB	atpF
atpH	atpA	atpG	atpD	atpC	glmU	fdhD	trmE
oxaA	rnpA	dnaA	recF	gyrB	rpmB	rpmG	rimO
PMI3182	secB	hslV	ftsN	rpmE	argC	murI	coaA
bfd	bfr	rplC	rplD	rplV	rplP	rpsQ	rplX
rpsN	rplF	rplR	rpsE	rpmD	secY	rpmJ	rpsM
rpoA	hdfR	PMI3296	ilvL	ilvG	trxA	rffT	rffM
hemX	cyaY	PMI3335	miaA	hflX	hflK	PMI3369	purA
rpsF	priB	rplI	argR	PMI3402	ispB	rplU	rpmA

obgE	PMI3410	rrmJ	ftsH	glmM	PMI3416	nusA	infB
pnp	nlpI	deaD	PMI3465	ivbL	ilvB	nark	frdC
frdB	frdA	poxA	ftsY	dusB	accB	aroQ	PMI3637
tldD	PMI3641	tldE	ptsN	rplM	diaA	PMI3691	PMI3692
PMI3693	PMI3694	cyoB	nuoM	zipA	dnaG	hyfF	murA

Table 13a: List of genes

zipA	secG	cyoC	pykF	flhB	dedA	crr	murF
gmhB	purH	PMI2939	fdoG	PMI3715	gpmB	dnaK	nhaA
ribF	ileS	carA	hyb0	hybA	hybB	hybD	cpdB
yajC	secD	secF	dxs	cyoE	cyoD	cyoB	tig
dnaG	priC	dnaX	PMI0140	recR	dksA	dksA	pyrG
eno	epd	fbaA	PMI0341	nqrC	rimM	trmD	rplS
PMI0392	lipA	lipB	corC	miaB	ubiF	gltA	sdhC
sdhA	sdhB	sucA	sucB	sucC	PMI0580	tolQ	tolB
pal	PMI0586	gpmA	PMI0648	clpA	serS	pflA	pflB
rpsA	aspC	ompF	asnC	pncB	rlmL	ompA	PMI0855
PMI0856	rpmF	plsX	fabH	fabG	fabF	lolC	PMI1014
proQ	thrS	rpmI	rplT	pheS	pheT	prsA	ipk
prfA	hemK	znuA	pykA	fumC	nth	rnb	tyrS
gapA	pgsA	uvrC	guaB	xseA	dapA	upp	purM
PMI1580	fliZ	fliA	fliG	fliK	fliL	fliN	flgB
flhA	cheY	cheB	cheR	PMI1665	PMI1666	motB	murA
nrdB	yfbB	nuoM	nuoL	nuoK	nuoJ	nuoI	nuoH
nuoG	nuoF	nuoE	nuoC	nuoA	PMI1763	PMI1767	ackA
purF	cvpA	fabB	ptsI	PMI1846	iscS	iscR	acnB
lpdA	aceF	ace	lpxC	ftsZ	ftsA	ftsQ	PMI2068
murC	mraZ	fold	ppiB	PMI2252	fabZ	lpxD	yaeT
ecfE	uppS	pyrH	tsf	rpsB	PMI2361	dnaG	rpoD
deoC	PMI2417	hyfD	hyfC	hyfB	hyfA	PMI2531	groL
groS	fixC	caiT	PMI2717	PMI2719	PMI2720	PMI2721	PMI2722
potA	PMI2745	uvrA	ssb	lexA	dgkA	plsB	PMI2770
PMI2772	rpoC	rpoB	rplL	rplJ	rplA	rplK	nusG
secE	fusA	rpsL	PMI2796	slyD	PMI2804	kefB	kefG
gmk	spoT	envZ	pstS	glpG	glpD	PMI2937	PMI2938
PMI2940	PMI2941	prlC	damX	gidA	atpI	atpB	atpF
atpH	atpA	atpG	atpD	atpC	glmU	fdhD	trmE
oxaA	rnpA	dnaA	recF	hyfF	rpmB	rpmG	rimO

PMI3182	secB	hslV	ftsN	rpmE	argC	murI	coaA
bfd	bfr	rplC	rplD	rplV	rplP	rpsQ	rplX
rpsN	rplF	rplR	rpsE	rpmD	secY	rpmJ	rpsM
rpoA	hdfR	PMI3296	ilvL	ilvG	trxA	rffT	rffM
hemX	cyaY	PMI3335	miaA	hflX	hflK	PMI3369	purA
rpsF	priB	rplI	argR	PMI3402	ispB	rplU	rpmA
obgE	PMI3410	rrmJ	ftsH	glmM	PMI3416	nusA	infB
pnp	nlpI	deaD	PMI3465	ivbL	ilvB	nark	frdC
frdB	frdA	poxA	ftsY	dusB	accB	aroQ	PMI3637
tldD	PMI3641	tldE	ptsN	rplM	diaA	PMI3691	PMI3692
PMI3693	PMI3694	cyoB	nuoM				

According to certain embodiments of the twenty-second, twenty-third, and/or twenty-fourth aspect, at least one of the following gene positions, preferably at least two, three, four, five, six, seven, eight, nine or more gene positions, is/are determined:

5
10
15
20
25

- 2562578, 3741905, 131826, 1482764, 1771087, 1771119, 1918241, 1968294,
- 2238063, 2238072, 2238088, 2238090, 2454709, 3039125, 3221491, 3221494,
- 3422635, 4059624, 4059634, 4060202, 131835, 19958, 21872, 25572, 25764,
- 25783, 26206, 26284, 32335, 32353, 53405, 53487, 53505, 53661, 53871,
- 54003, 54004, 54213, 54276, 54303, 54468, 54605, 55215, 55677, 55735,
- 56361, 56639, 58576, 58578, 68312, 105758, 106230, 106253, 107791,
- 122332, 131111, 131404, 131446, 132270, 132397, 141518, 141519, 142045,
- 142682, 165937, 166053, 166099, 166157, 166159, 166167, 166180, 171360,
- 171546, 171658, 171662, 174515, 174869, 175036, 236145, 236466, 262760,
- 263053, 289363, 291016, 291155, 291404, 390045, 390048, 404430, 438564,
- 438569, 438583, 438625, 438977, 439953, 447813, 488253, 488635, 489064,
- 512855, 515772, 516200, 609454, 609606, 610448, 610581, 610582, 610593,
- 610594, 612627, 612638, 612639, 612694, 612843, 613447, 613821, 613863,
- 613937, 613949, 614135, 614251, 616159, 616177, 616207, 616215, 616221,
- 616298, 616300, 616305, 616353, 616661, 616780, 616841, 616890, 616939,
- 617048, 618013, 618168, 628162, 628863, 631669, 631775, 632026, 632027,
- 632122, 632126, 632133, 632140, 632142, 632197, 632399, 632442, 632560,
- 632720, 637570, 704521, 749216, 764862, 764899, 764902, 764903, 764904,
- 764954, 769675, 771332, 771477, 771623, 771729, 771731, 784768, 785214,
- 785336, 848303, 849825, 851231, 852902, 860929, 873905, 947084, 947158,
- 947163, 947167, 947173, 947182, 947210, 947236, 947252, 947254, 947296,
- 947564, 947656, 947738, 947807, 947816, 947821, 947926, 947927, 947928,
- 948092, 948099, 948576, 948742, 949052, 949151, 949185, 949189, 949198,

949339, 949415, 949416, 949441, 949454, 949458, 949467, 949474, 949544,
949559, 949663, 951242, 951244, 951248, 951254, 951360, 951854, 951902,
952495, 952747, 952828, 952836, 968923, 1077386, 1077419, 1077468,
1077618, 1077724, 1078112, 1100144, 1100989, 1101393, 1101438, 1101919,
5 1101980, 1101994, 1104454, 1104820, 1104839, 1104869, 1105039, 1105097,
1105100, 1146632, 1146937, 1147549, 1147625, 1147626, 1147771, 1150615,
1150731, 1152456, 1212590, 1212620, 1212736, 1212743, 1212788, 1217061,
1371149, 1385767, 1385770, 1385787, 1386122, 1386278, 1464863, 1464864,
1464866, 1464868, 1465085, 1482775, 1596063, 1596215, 1596441, 1614151,
10 1614206, 1614352, 1614378, 1614858, 1615063, 1615065, 1615072, 1640778,
1640933, 1640990, 1641451, 1662486, 1673731, 1673848, 1674401, 1680613,
1731860, 1732817, 1732858, 1745743, 1748563, 1749691, 1749694, 1749702,
1749817, 1749878, 1750174, 1750252, 1750255, 1750318, 1750335, 1750351,
1750378, 1750387, 1750467, 1750477, 1750489, 1750499, 1750500, 1750515,
15 1750516, 1751645, 1764702, 1770887, 1771129, 1771251, 1771265, 1771266,
1773358, 1773359, 1773362, 1773396, 1773580, 1773746, 1775351, 1777128,
1777130, 1777396, 1777408, 1777703, 1782242, 1853651, 1853822, 1857896,
1866823, 1875173, 1875189, 1875301, 1876427, 1876529, 1876536, 1876822,
1876979, 1876980, 1876981, 1876996, 1877004, 1877005, 1878333, 1878585,
20 1878600, 1878732, 1878856, 1879024, 1879091, 1879137, 1879282, 1879349,
1879919, 1880000, 1880555, 1880557, 1881003, 1881096, 1881108, 1881129,
1881144, 1881154, 1881155, 1881168, 1881171, 1883439, 1883753, 1883897,
1883933, 1883937, 1884932, 1885231, 1885531, 1885549, 1885601, 1887186,
1887195, 1887200, 1887371, 1888236, 1888332, 1888582, 1888605, 1888971,
25 1894922, 1897741, 1914231, 1914232, 1914319, 1914381, 1914385, 1914632,
1925721, 1967765, 1967784, 1983874, 2000892, 2002419, 2183724, 2199454,
2200254, 2200493, 2200898, 2201059, 2201120, 2201122, 2201708, 2202174,
2202175, 2202457, 2202981, 2203212, 2203250, 2203904, 2203927, 2203955,
2205132, 2205184, 2227683, 2228236, 2229346, 2229439, 2229621, 2229622,
30 2229648, 2230617, 2230750, 2230836, 2230874, 2231569, 2231570, 2231571,
2231581, 2231794, 238100, 2243936, 2335800, 2340329, 2442677, 2442685,
2472332, 2473402, 2476250, 2476332, 2476597, 2476603, 2476615, 2476742,
2478782, 2478897, 2481987, 2482024, 2482224, 2482760, 2482761, 2482867,
2483098, 2483108, 2483232, 2483791, 2581759, 2590008, 2590377, 2592098,
35 2644614, 2644726, 2644737, 2769143, 2769146, 2769209, 2769248, 2769288,
2772170, 2772179, 2772279, 2772642, 2775062, 2775162, 2775272, 2786911,
2786926, 2787314, 2787433, 2787446, 2787447, 2787827, 2787951, 2788142,
2788300, 2788384, 2788451, 2788539, 2788541, 2788586, 2898978, 2904023,
2968996, 2969025, 2969694, 2969753, 2969784, 2969798, 2971794, 2971795,
40 2971796, 2971797, 2971798, 2971959, 2972346, 2972726, 2988736, 2988934,

3000293, 3000434, 3003519, 3003544, 3003546, 3004546, 3004697, 3006261,
3006611, 3006612, 3006613, 3006627, 3006658, 3006708, 3006709, 3006715,
3006791, 3006810, 3006832, 3006847, 3006902, 3006904, 3006910, 3007284,
3007321, 3007477, 3041804, 3041820, 3041823, 3042357, 3042468, 3055027,
5 3055162, 3055257, 3055258, 3055273, 3055564, 3058839, 3058882, 3059496,
3059509, 3059675, 3059676, 3059963, 3060607, 3060792, 3060994, 3061157,
3061158, 3061179, 3061620, 3062379, 3062488, 3062683, 3062701, 3062723,
3062866, 3062945, 3063015, 3063544, 3064080, 3064098, 3064099, 3064103,
3064277, 3064283, 3065011, 3065028, 3065306, 3065502, 3065511, 3065512,
10 3065580, 3067456, 3067463, 3067493, 3067563, 3067579, 3067693, 3067720,
3067731, 3067732, 3067739, 3067798, 3067942, 3068551, 3069985, 3070082,
3070525, 3070560, 3070598, 3070599, 3070610, 3070624, 3070666, 3070672,
3070699, 3075527, 3075770, 3075960, 3076139, 3076150, 3076157, 3076168,
3076170, 3078449, 3078450, 3140400, 3140993, 3141038, 3173976, 3173988,
15 3173997, 3174309, 3174402, 3174403, 3174429, 3174528, 3174529, 3174532,
3174594, 3174618, 3174619, 3174632, 3210333, 3210381, 3210582, 3210583,
3211688, 3211694, 3211774, 3220249, 3220312, 3220529, 3220580, 3220803,
3220811, 3220832, 3220880, 3220883, 3220965, 3221159, 3221172, 3221380,
3221587, 3221611, 3223265, 3225405, 3225451, 3225529, 3299712, 3299749,
20 3326024, 3358602, 3361509, 3361588, 3361606, 3361612, 3361614, 3361621,
3361871, 3361872, 3361937, 3361992, 3361994, 3362009, 3362011, 3362031,
3362078, 3362345, 3362393, 3363067, 3363185, 3363326, 3363663, 3363684,
3363730, 3363803, 3363969, 3364748, 3364941, 3364955, 3364959, 3364963,
3365950, 3365960, 3365994, 3366006, 3366059, 3366266, 3366827, 3366832,
25 3367976, 3367999, 3368000, 3368115, 3368631, 3421606, 3422011, 3422089,
3422272, 3422315, 3422593, 3422660, 3422746, 3422758, 3422800, 3422827,
3422947, 3422998, 3423002, 3423301, 3423314, 3423339, 3423347, 3423349,
3423479, 3423571, 3423572, 3423593, 3423641, 3442266, 3442411, 3442455,
3442482, 3442995, 3443468, 3443474, 3443514, 3443600, 3443627, 3443740,
30 3443741, 3443807, 3443816, 3443933, 3443937, 3443945, 3443948, 3443951,
3443952, 3443954, 3444678, 3444693, 3444702, 3446029, 3446261, 3446713,
3446933, 3448971, 3448972, 3448991, 3449040, 3449042, 3449052, 3449075,
3449081, 3449123, 3449280, 3449348, 3449349, 3449403, 3449612, 3449698,
3449885, 3449889, 3449925, 3449970, 3450028, 3450545, 3450640, 3470490,
35 3470647, 3470648, 3496360, 3496871, 3496900, 3497196, 3497557, 3497558,
3497560, 3530618, 3530628, 3530903, 3531614, 3531625, 3531774, 3531804,
3535639, 3557063, 3557092, 3557151, 3568751, 3568760, 3568840, 3568944,
3568978, 3578816, 3578860, 3578891, 3581355, 3581400, 3581673, 3581980,
3582010, 3582844, 3583192, 3583558, 3583833, 3585451, 3585537, 3585546,
40 3586561, 3586562, 3586567, 3586831, 3586849, 3587263, 3587297, 3587299,

3588101, 3588942, 3589709, 3589828, 3589840, 3589862, 3589930, 3590344,
3590345, 3590700, 3590900, 3591026, 3591624, 3591647, 3593035, 3593310,
3593315, 3595160, 3595163, 3595208, 3612449, 3612512, 3612769, 3612829,
3612890, 3612907, 3612935, 3613063, 3613446, 3613509, 3615780, 3615990,
5 3632585, 3632588, 3632597, 3632608, 3644924, 3645043, 3647693, 3647816,
3647822, 3647885, 3647911, 3652470, 3658169, 3658352, 3692300, 3692462,
3692463, 3692464, 3692465, 3692477, 3694213, 3694436, 3696887, 3696968,
3696971, 3697375, 3703133, 3703141, 3703214, 3703248, 3703310, 3703384,
3703388, 3704011, 3704123, 3727857, 3727858, 3730091, 3731610, 3732055,
10 3732064, 3732455, 3732867, 3736431, 3736432, 3737164, 3737782, 3741525,
3741540, 3741553, 3741562, 3741571, 3742055, 3742803, 3742837, 3742916,
3742967, 3743001, 3743006, 3743365, 3743369, 3743419, 3743430, 3743434,
3743435, 3743436, 3743453, 3743622, 3743713, 3743794, 3743802, 3744367,
3744368, 3744390, 3744402, 3744517, 3744612, 3744870, 3744951, 3745026,
15 3745062, 3745264, 3745279, 3745282, 3745433, 3745437, 3745460, 3749482,
3749941, 3749942, 3752300, 3752306, 3752575, 3752583, 3752605, 3753216,
3793195, 3838549, 3838757, 3838877, 3838879, 3838939, 3899203, 3917376,
3917431, 3918057, 3918248, 3918273, 3918304, 3918459, 3918870, 3921420,
3921481, 3942358, 3943893, 3944031, 3960166, 3960289, 3960435, 3960436,
20 3960447, 3960448, 3960566, 3960569, 3960577, 3960778, 3965450, 3965463,
3965465, 3965787, 3965944, 3966152, 3966202, 3966203, 3966226, 3977953,
3978005, 3980725, 3980737, 3980791, 3980810, 3980884, 3981160, 3981182,
3984702, 3984759, 3984780, 4005175, 4005457, 4029846, 4030230, 4030296,
4030298, 4030314, 4030336, 4030378, 4030434, 4030446, 4030541, 4032086,
25 4032192, 4032215, 4032242, 4032245, 4032266, 4032293, 4032332, 4032335,
4032343, 4032365, 4032713, 4032870, 4033003, 4033006, 4033170, 4033178,
4033231, 4033240, 4033241, 4033242, 4033245, 4033249, 4033255, 4033359,
4033382, 4033392, 4033958, 4034032, 4034039, 4034044, 4034054, 4034064,
4034069, 4034095, 4034111, 4034132, 4034134, 4034139, 4034147, 4034167,
30 4034192, 4034231, 4034237, 4034261, 4060077, 4060130, 4060144, 4060163,
4060171, 4060243, 132508, 1875294, 1963153, 2590425, 2766897, 3995229.

Examples

35

The present invention will now be described in detail with reference to several examples thereof. However, these exam-

ples are illustrative and do not limit the scope of the invention.

Example 1

5 Whole genome sequencing was carried out in addition to classical antimicrobial susceptibility testing of the same isolates for a cohort of 583 specimens of *Proteus* species, particularly *Proteus mirabilis*, *Proteus penneri* and *Proteus vul-*
10 *garis*. This allowed performing genome wide correlation studies to find genetic variants (e.g. point mutations, small insertions and deletion, larger structural variants, plasmid copy number gains, gene dosage effects) in the genome and plasmids that are significantly correlated to the resistance against one or several drugs. The approach also allows for
15 comparing the relevant sites in the genome to each other.

In the approach the different sources of genetic resistance as well as the different ways of how bacteria can become resistant were covered. By measuring clinical isolates collect-
20 ed in a broad geographical area and across a broad time span of three decades a complete picture going far beyond the rather artificial step of laboratory generated resistance mechanisms was tried to be generated.

25 To this end, a set of 21 clinically relevant antimicrobial agents with 5 different modes of action was put together, and the minimally inhibitory concentration (MIC) of the 21 drugs for the *Proteus* isolates was measured.

30 The detailed procedure is given in the following:

Bacterial Strains

The inventors selected 583 *Proteus* strains from the microbiology strain collection at Siemens Healthcare Diagnostics (West Sacramento, CA) for susceptibility testing and whole genome sequencing.

5 Antimicrobial Susceptibility Testing (AST) Panels
Frozen reference AST panels were prepared following Clinical Laboratory Standards Institute (CLSI) recommendations. The following antimicrobial agents (with $\mu\text{g/ml}$ concentrations shown in parentheses) were included in the panels: Amoxicillin/K Clavulanate (0.5/0.25-64/32), Ampicillin (0.25-128),
10 Ampicillin/Sulbactam (0.5/0.25-64/32), Aztreonam (0.25-64), Cefazolin (0.5-32), Cefepime (0.25-64), Cefotaxime (0.25-128), Ceftazidime (0.25-64), Ceftriaxone (0.25-128), Cefuroxime (1-64), Cephalothin (1-64), Ciprofloxacin (0.015-8),
15 Ertepenem (0.12-32), Gentamicin (0.12-32), Imipenem (0.25-32), Levofloxacin (0.25-16), Meropenem (0.12-32), Piperacillin/Tazobactam (0.25/4-256/4), Tetracycline (0.5-64), Tobramycin (0.12-32), and Trimethoprim/Sulfamethoxazole (0.25/4.7-32/608). Prior to use with clinical isolates, AST
20 panels were tested with QC strains. AST panels were considered acceptable for testing with clinical isolates when the QC results met QC ranges described by CLSI16.

Inoculum Preparation

25 Isolates were cultured on trypticase soy agar with 5% sheep blood (BBL, Cockeysville, Md.) and incubated in ambient air at $35\pm 1^\circ\text{C}$ for 18-24 h. Isolated colonies (4-5 large colonies or 5-10 small colonies) were transferred to a 3 ml Sterile Inoculum Water (Siemens) and emulsified to a final turbidity
30 of a 0.5 McFarland standard. 2 ml of this suspension was added to 25 ml Inoculum Water with Pluronic-F (Siemens). Using the Inoculator (Siemens) specific for frozen AST panels, 5 μl of the cell suspension was transferred to each well of the

AST panel. The inoculated AST panels were incubated in ambient air at $35\pm 1^\circ\text{C}$ for 16-20 h. Panel results were read visually, and minimal inhibitory concentrations (MIC) were determined.

5

DNA extraction

Four streaks of each Gram-negative bacterial isolate cultured on trypticase soy agar containing 5% sheep blood and cell suspensions were made in sterile 1.5 ml collection tubes containing 50 μl Nuclease-Free Water (AM9930, Life Technologies). Bacterial isolate samples were stored at -20°C until nucleic acid extraction. The Tissue Preparation System (TPS) (096D0382-02_01_B, Siemens) and the VERSANT[®] Tissue Preparation Reagents (TPR) kit (10632404B, Siemens) were used to extract DNA from these bacterial isolates. Prior to extraction, the bacterial isolates were thawed at room temperature and were pelleted at 2000 G for 5 seconds. The DNA extraction protocol DNAext was used for complete total nucleic acid extraction of 48 isolate samples and eluates, 50 μl each, in 4 hours. The total nucleic acid eluates were then transferred into 96-Well qPCR Detection Plates (401341, Agilent Technologies) for RNase A digestion, DNA quantitation, and plate DNA concentration standardization processes. RNase A (AM2271, Life Technologies) which was diluted in nuclease-free water following manufacturer's instructions was added to 50 μl of the total nucleic acid eluate for a final working concentration of 20 $\mu\text{g}/\text{ml}$. Digestion enzyme and eluate mixture were incubated at 37°C for 30 minutes using Siemens VERSANT[®] Amplification and Detection instrument. DNA from the RNase digested eluate was quantitated using the Quant-iT[™] PicoGreen dsDNA Assay (P11496, Life Technologies) following the assay kit instruction, and fluorescence was determined on the Siemens VERSANT[®] Amplification and Detection instrument. Data

10
15
20
25
30

analysis was performed using Microsoft® Excel 2007. 25 µl of the quantitated DNA eluates were transferred into a new 96-Well PCR plate for plate DNA concentration standardization prior to library preparation. Elution buffer from the TPR kit was used to adjust DNA concentration. The standardized DNA eluate plate was then stored at -80°C until library preparation.

Next Generation Sequencing

Prior to library preparation, quality control of isolated bacterial DNA was conducted using a Qubit 2.0 Fluorometer (Qubit dsDNA BR Assay Kit, Life Technologies) and an Agilent 2200 TapeStation (Genomic DNA ScreenTape, Agilent Technologies). NGS libraries were prepared in 96 well format using NexteraXT DNA Sample Preparation Kit and NexteraXT Index Kit for 96 Indexes (Illumina) according to the manufacturer's protocol. The resulting sequencing libraries were quantified in a qPCR-based approach using the KAPA SYBR FAST qPCR MasterMix Kit (Peqlab) on a ViiA 7 real time PCR system (Life Technologies). 96 samples were pooled per lane for paired-end sequencing (2x 100bp) on Illumina HiSeq2000 or HiSeq2500 sequencers using TruSeq PE Cluster v3 and TruSeq SBS v3 sequencing chemistry (Illumina). Basic sequencing quality parameters were determined using the FastQC quality control tool for high throughput sequence data (Babraham Bioinformatics Institute).

Data analysis

Raw paired-end sequencing data for the 583 Proteus samples were mapped against the Proteus reference (NC_010554) with BWA 0.6.1.20. The resulting SAM files were sorted, converted to BAM files, and PCR duplicates were marked using the Picard tools package 1.104 (<http://picard.sourceforge.net/>). The Ge-

nome Analysis Toolkit 3.1.1 (GATK)²¹ was used to call SNPs and indels for blocks of 200 Proteus samples (parameters: -ploidy 1 -glm BOTH -stand_call_conf 30 -stand_emit_conf 10). VCF files were combined into a single file and quality filtering for SNPs was carried out (QD < 2.0 || FS > 60.0 || MQ < 40.0) and indels (QD < 2.0 || FS > 200.0). Detected variants were annotated with SnpEff²² to predict coding effects. For each annotated position, genotypes of all Proteus samples were considered. Proteus samples were split into two groups, low resistance group (having lower MIC concentration for the considered drug), and high resistance group (having higher MIC concentrations) with respect to a certain MIC concentration (breakpoint). To find the best breakpoint all thresholds were evaluated and p-values were computed with Fisher's exact test relying on a 2x2 contingency table (number of Proteus samples having the reference or variant genotype vs. number of samples belonging to the low and high resistance group). The best computed breakpoint was the threshold yielding the lowest p-value for a certain genomic position and drug. For further analyses positions with non-synonymous alterations and p-value < 10^{-10} were considered.

Since a potential reason for drug resistance is gene duplication, gene dose dependency was evaluated. For each sample the genomic coverage for each position was determined using BED Tools. Gene ranges were extracted from the reference assembly NC_010554.gff and the normalized median coverage per gene was calculated. To compare low- and high-resistance isolates the best area under the curve (AUC) value was computed. Groups of at least 20% of all samples having a median coverage larger than zero for that gene and containing more than 15 samples per group were considered in order to exclude artifacts and cases with AUC > 0.75 were further evaluated.

To include data on the different ways how resistance mechanisms are acquired Proteus isolates collected over more than three decades were analyzed such that also horizontal gene transfer could potentially be discovered.

In detail, the following steps were carried out:
Proteus strains to be tested were seeded on agar plates and incubated under growth conditions for 24 hours. Then, colonies were picked and incubated in growth medium in the presence of a given antibiotic drug in dilution series under growth conditions for 16-20 hours. Bacterial growth was determined by observing turbidity.

Next mutations were searched that are highly correlated with the results of the phenotypic resistance test.

For sequencing, samples were prepared using a Nextera library preparation, followed by multiplexed sequencing using the Illuminat HiSeq 2500 system, paired end sequencing. Data were mapped with BWA (Li H. and Durbin R. (2010) Fast and accurate long-read alignment with Burrows-Wheeler Transform. Bioinformatics, Epub. [PMID: 20080505]) and SNP were called using samtools (Li H.*, Handsaker B.*, Wysoker A., Fennell T., Ruan J., Homer N., Marth G., Abecasis G., Durbin R. and 1000 Genome Project Data Processing Subgroup (2009) The Sequence alignment/map (SAM) format and SAMtools. Bioinformatics, 25, 2078-9. [PMID: 19505943]).

As reference genome, NC_010554 as annotated at the NCBI was determined as best suited.

The mutations were matched to the genes and the amino acid changes were calculated. Using different algorithms (SVM, ho-

mology modeling) mutations leading to amino acid changes with likely pathogenicity / resistance were calculated.

In total, whole genomes and plasmids of 583 different clinical isolates of *Proteus* species were sequenced, and classical antimicrobial susceptibility testing (AST) against 21 therapy forms as described above was performed for all organisms. From the classical AST a table with 583 rows (isolates) and 21 columns (MIC values for 21 drugs) was obtained. Each table entry contained the MIC for the respective isolate and the respective drug. The genetic data were mapped to different reference genomes of *Proteus* that have been annotated at the NCBI (<http://www.ncbi.nlm.nih.gov/>), and the best reference was chosen as template for the alignment - NC_010554 as annotated at the NCBI. Additionally, assemblies were carried out and it was verified that the sequenced genomes fulfil all quality criteria to become reference genomes.

Next, genetic variants were evaluated. This approach resulted in a table with the genetic sites in columns and the same isolates in 583 rows. Each table entry contained the genetic determinant at the respective site (A, C, T, G, small insertions and deletions, ...) for the respective isolate.

In a next step different statistical tests were carried out

- 1) For comparing resistance / susceptibility to genetic sites we calculated contingency tables and determined the significance using Fishers test
- 2) For comparing different sites to each other we calculated the correlation between different genetic sites
- 3) For detecting gene dosage effects, e.g. loss or gain of genes (in the genome or on plasmids) we calculated the coverage (i.e. how many read map to the current posi-

tion) at each site for resistant and not resistant isolates.

From the data, first the 21 genes with the best p-value were
5 chosen for the list of mutations as well as the list of correlated antibiotic resistance, representing Tables 1 and 2. As for a lot of genes the p-values were very low, also the next p-values up to $1,04565E-62$ were considered, leading to the genes in Table 13 and Table 13a, respectively the gene
10 positions disclosed with regard to the 22nd, 23rd and/or 24th aspect.

A full list of all genetic sites, drugs, drug classes, affected genes etc. is provided in Tables 3 and 4a, 4b and 4c,
15 wherein Table 3 corresponds to Table 1 and represents the genes having the lowest p-values after determining mutations in the genes, and Table 4, respectively Tables 4a, 4b and 4c correspond to Table 2 and represent the genes having the lowest p-values after correlating the mutations with antibiotic
20 resistance for the respective antibiotics.

In addition, the data with the best p-values for each antibiotic class with the most antibiotic drugs, as well as each antibiotic, respectively, were evaluated, being disclosed in
25 Tables 5 - 10.

In Tables 3 - 10 the columns are designated as follows:

Gene name: affected gene;

POS: genomic position of the SNP / variant in the Proteus
30 reference genome (see above);

p-value: significance value calculated using Fishers exact test (determined according to FDR (Benjamini Hochberg) method (Benjamini Hochberg, 1995));

genbank protein accession number: (NCBI) Accession number of
the corresponding protein of the genes

Table 3: Detailed results for the genes in Example 1 (corresponding to Table 1)

POS	drug class	#drug classes	p-value	gene name	genbank protein accession number
2562578	other (benzene derived)/sulfonamide; amino-glycoside; fluoroquinolone;Lactams	4	4,65979E-71	parC	YP_002152062.1
3741905	fluoroquinolone;polyketide*;Lactams	3	5,11728E-63	secG	YP_002153099.1
131826	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	cyoC	YP_002149890.1
1482764	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	pykF	YP_002151136.1
1771087	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	flhB	YP_002151391.1
1771119	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	flhB	YP_002151391.1
1918241	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	dedA	YP_002151518.1
1968294	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	crr	YP_002151557.1
2238063	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	murF	YP_002151793.1
2238072	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	murF	YP_002151793.1
2238088	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	murF	YP_002151793.1
2238090	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	murF	YP_002151793.1
2454709	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	gmhB	YP_002151976.1
3039125	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	purH	YP_002152469.1
3221491	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	PMI2939	YP_002152640.1
3221494	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	PMI2939	YP_002152640.1
3422635	other (benzene derived)/sulfonamide; polyketide*;fluoroquinolone; Lactams	4	7,38724E-63	fdoG	YP_002152801.1
4059624	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	PMI3715	YP_002153390.1

4059634	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	PMI3715	YP_0021533390.1
4060202	fluoroquinolone;polyketide*;Lactams	3	7,38724E-63	gpmB	YP_0021533391.1
131835	fluoroquinolone;polyketide*;Lactams	3	8,38542E-63	cyoC	YP_002149890.1

*: (tetracycline)

Table 4a: Detailed results for the genes in Example 1 (corresponding to Table 2)

POS	drug	#drugs	drug class	#drug classes
2562578	CF; T/S; CP; CFT; GM; CFZ; CRM; CAX; CPE; AM; A/S; LVX; AUG	13	other (benzene derived) /sulfonamide; aminoglycoside; fluoroquinolone; Lactams	4
3741905	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
131826	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
1482764	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
1771087	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
1771119	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
1918241	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
1968294	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
2238063	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
2238072	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
2238088	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
2238090	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
2454709	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	10	fluoroquinolone; polyketide*; Lactams	3
3039125	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	10	fluoroquinolone; polyketide*; Lactams	3
3221491	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
3221494	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
3422635	CF; T/S; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	other (benzene derived) /sulfonamide; polyketide*; fluoroquinolone; Lactams	4
4059624	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3

4059634	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
4060202	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3
131835	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	3

*: (tetracycline)

Table 4b: Detailed results for the genes in Example 1 (corresponding to Table 2, continued)

POS	best drug	#significant Lactams	#significant fluoroquinolones	#significant aminoglycosides	#significant polyketide (tetracycline)	#significant other (benzene derived)/ sulfonamide
2562578	CP	9	2	1	0	1
3741905	CFZ	8	2	0	1	0
131826	CFZ	8	2	0	1	0
1482764	CFZ	8	2	0	1	0
1771087	CFZ	8	2	0	1	0
1771119	CFZ	8	2	0	1	0
1918241	CFZ	8	2	0	1	0
1968294	CFZ	8	2	0	1	0
2238063	CFZ	8	2	0	1	0
2238072	CFZ	8	2	0	1	0
2238088	CFZ	8	2	0	1	0
2238090	CFZ	8	2	0	1	0
2454709	TE	7	2	0	1	0
3039125	TE	7	2	0	1	0
3221491	CFZ	8	2	0	1	0
3221494	CFZ	8	2	0	1	0
3422635	TE	7	2	0	1	1
4059624	CFZ	8	2	0	1	0

4059634	CFZ	8	2	0	1	0	0
4060202	CFZ	8	2	0	1	0	0
131835	CFZ	8	2	0	1	0	0

Table 4c: Detailed results for the genes in Example 1 (corresponding to Table 2, continued)

POS	p-value	gene name	genbank protein accession number
2562578	4, 65979E-71	parC	YP 002152062.1
3741905	5, 11728E-63	secG	YP 002153099.1
131826	7, 38724E-63	cyoC	YP 002149890.1
1482764	7, 38724E-63	pykF	YP 002151136.1
1771087	7, 38724E-63	flhB	YP 002151391.1
1771119	7, 38724E-63	flhB	YP 002151391.1
1918241	7, 38724E-63	dedA	YP 002151518.1
1968294	7, 38724E-63	crr	YP 002151557.1
2238063	7, 38724E-63	murF	YP 002151793.1
2238072	7, 38724E-63	murF	YP 002151793.1
2238088	7, 38724E-63	murF	YP 002151793.1
2238090	7, 38724E-63	murF	YP 002151793.1
2454709	7, 38724E-63	gmhB	YP 002151976.1
3039125	7, 38724E-63	purH	YP 002152469.1
3221491	7, 38724E-63	PMI2939	YP 002152640.1
3221494	7, 38724E-63	PMI2939	YP 002152640.1
3422635	7, 38724E-63	fdoG	YP 002152801.1
4059624	7, 38724E-63	PMI3715	YP 002153390.1
4059634	7, 38724E-63	PMI3715	YP 002153390.1
4060202	7, 38724E-63	gpmB	YP 002153391.1
131835	8, 38542E-63	cyoC	YP 002149890.1

Also the antibiotic/drug classes, the number of significant antibiotics correlated to the mutations (over all antibiotics or over certain classes), as well as the correlated antibiotics are denoted in the Tables.

5

The p-value was calculated using the Fisher exact test based on contingency table with 4 fields: #samples Resistant / wild type; #samples Resistant / mutant; #samples not Resistant / wild type; #samples not Resistant / mutant

10

The test is based on the distribution of the samples in the 4 fields. Even distribution indicates no significance, while clustering into two fields indicates significance.

15 The following results were obtained

- A total of 27.140 different correlations between genetic sites and anti-microbial agents were detected (p-value < 10^{-10}).

20 - The biggest part of these were point mutations (i.e. single base exchanges)

- The highest significance (10^{-71}) was reached for a non-synonymous coding in YP_002152062.1, particular in position 2562578 with regard to reference genome NC_010554 as annotated at the NCBI, which is a non-synonymous coding, particularly a codon change aGc/aTc

25

- Besides these, insertions or deletions of up to four bases were discovered

- Further, potential genetic tests for five different drug classes relating to resistances were discovered

30

- β -lactams (includes Penicillins, Cephalosporins, Carbapenems, Monobactams)
- Quinolones, particularly Fluoroquinolones
- Aminoglycosides

- Polyketides, particularly Tetracyclines
- Folate synthesis inhibitors

- Potential genetic tests for all tested drugs/drug combinations were discovered:

- 5 Amoxicillin/Clavulanate, Ampicillin, Ampicillin/Sulbactam, Aztreonam, Cefazolin, Cefepime, Ceftazidime, Cefuroxime, Cephalothin, Imipenem, Piperacillin/Tazobactam, Ciprofloxacin, Levofloxacin, Gentamycin, Tobramycin, Tetracycline, Trimethoprim/Sulfamethoxazol
- 10 - Mutations were observed in 2.223 different genes

While in the tables only the best mutations in each gene are represented, a manifold of different SNPs has been found for each gene. Examples for multiple SNPs for two of the genes
15 given in Table 5 (respectively Table 10) are shown in the following Tables 14 and 15 (headers as in Tables 3 and 4).

Table 14: Statistically significant SNPs in gene dnaK (genbank protein accession number YP_002149796.1) (headers as in Tables 3 and 4, respectively)

POS	drug	#drugs	drug class	best drug	p-value
19947	CF; TE; CFZ; CRM; AM; A/S	6	polyketide*; Lactams	CFZ	6.4611E-026
18189	CF; TE; CFZ; CRM; CP; AM; A/S; AUG	8	fluoroquinolone; polyketide*; Lactams	TE	5.6584E-042
18338	CF; TE; CFZ; CRM; CP; AM	6	fluoroquinolone; polyketide*; Lactams	TE	2.2606E-024
19061	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide* Lactams	CFZ	8.7045E-061
18893	CF; TE; CFZ; CRM; CP; AM	6	fluoroquinolone; polyketide*; Lactams	TE	6.5221E-024
18503	CF; CFZ; TE; CRM	4	polyketide*; Lactams	TE	1.8709E-031
19630	CF; TE; CFZ; CRM; CAX; AM; AUG	7	polyketide*; Lactams	CRM	5.7027E-018
18339	CF; TE; CFZ; CRM; CP; AM	6	fluoroquinolone; polyketide*; Lactams	TE	2.3907E-028
18380	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	10	fluoroquinolone; polyketide*; Lactams	CFZ	4.2782E-059
19954	CF; TE; CFZ; CRM; CP; AM	6	fluoroquinolone; polyketide*; Lactams	TE	1.3307E-022
19888	CF; T/S; TE; CFZ; CRM; CP; CAX; AM; A/S; AUG	10	other (benzene derived)/sulfonamide; polyketide*; fluoroquinolone; Lactams	TE	1.0336E-043
19941	CF; CFZ; TE; CRM; AM	5	polyketide*; Lactams	CFZ	1.0492E-020
19062	CF; TE; CFT; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	fluoroquinolone; polyketide*; Lactams	CFZ	8.7045E-061
18359	CF; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	10	fluoroquinolone; polyketide*; Lactams	CFZ	4.0853E-051
19958	CF; T/S; TE; CFZ; CRM; CP; CAX; LVX; AM; A/S; AUG	11	other (benzene derived)/sulfonamide; fluoroquinolone; polyketide*; Lactams	TE	1.0456E-062
19891	CF; TE; CFZ; CRM; CP; AM; A/S; AUG	8	fluoroquinolone; polyketide*; Lactams	CFZ	3.7374E-028
19772	CF; TE; CFZ; CRM; CP; CAX; AM; A/S; AUG	9	fluoroquinolone; polyketide*; Lactams	CFZ	3.0990E-043

19054	CF;CFZ;TE;CRM;AM		5	polyketide*;Lactams	CFZ	1.8540E-016
19926	CF;T/S;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	10	other (benzene derived)/sulfonamide; fluoroquinolone; polyketide*;Lactams	CFZ	5.4187E-042	
18581	CF;T/S;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	10	other (benzene derived)/sulfonamide; fluoroquinolone; polyketide*;Lactams	TE	3.9631E-046	
19165	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	CFZ	3.1584E-056	
18334	CF;CFZ;TE;CRM	4	polyketide*;Lactams	TE	1.2022E-011	
18168	CF;TE;CFZ;CRM;CAX;AM	6	polyketide*;Lactams	CRM	6.5296E-016	
19100	CF;TE;CFZ;CRM;CP;AM	6	fluoroquinolone; polyketide*;Lactams	TE	8.1028E-035	
18582	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	CFZ	6.4561E-037	
19862	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	CFZ	3.1384E-051	
19949	CF;CFZ;CRM;CAX;AM;AUG	6	Lactams	CRM	2.9366E-014	
18500	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	11	fluoroquinolone; polyketide*;Lactams	CFZ	1.0809E-061	
19948	CF;TE;CFZ;CRM;CP;AM;A/S;AUG	8	fluoroquinolone; polyketide*;Lactams	TE	2.7920E-038	
19845	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	CFZ	2.9595E-044	
19338	CF;CFZ;CRM;CAX	4	Lactams	CRM	9.54021E-016	
19884	CF;T/S;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	10	other (benzene derived)/sulfonamide; fluoroquinolone; polyketide*;Lactams	TE	6.5997E-045	
19868	CF;CFZ;CRM	3	Lactams	CRM	1.6144E-010	
19946	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	TE	2.9201E-050	
19937	CF;TE;CFZ;CRM;CP;AM;A/S;AUG	8	fluoroquinolone; polyketide*;Lactams	TE	8.0399E-038	
18407	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	TE	2.7572E-055	
19805	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	CFZ	3.1384E-051	

18188	CF;CFZ;CRM;CAX	4	Lactams	CRM	1.2444E-014
19865	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	CFZ	3.1384E-051
18424	CF;TE;CFZ;CRM;CP;AM	6	fluoroquinolone; polyketide*;Lactams	TE	6.6609E-024
18617	CF;CFZ;TE;CRM;AM	5	polyketide*;Lactams	CFZ	5.4482E-019
19927	CF;TE;CFZ;CRM;CAX;AM;A/S;AUG	8	polyketide*;Lactams	CFZ	1.5455E-033
18592	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	11	fluoroquinolone; polyketide*;Lactams	CFZ	1.1912E-062
19945	CF;CFZ;TE;CRM;AM	5	polyketide*;Lactams	TE	1.3405E-023
	CF;T/S;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S		other (benzene derived)/sulfonamide;		
18585	;AUG	12	fluoroquinolone; polyketide*;Lactams	CFZ	1.8102E-060
19490	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG	9	fluoroquinolone; polyketide*;Lactams	CFZ	1.1113E-041
19944	CF;TE;CFZ;CRM;CAX;AM;AUG	7	polyketide*;Lactams	CRM	9.2056E-020
19063	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	11	fluoroquinolone; polyketide*;Lactams	CFZ	3.1780E-060
18588	CF;TE;CFT;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG	11	fluoroquinolone; polyketide*;Lactams	CFZ	1.1912E-062

*: (tetracycline)

Table 15: Statistically significant SNPs in gene nhaA (genbank protein accession number YP_002149798.1) (headers as in Tables 3 and 4, respectively)

POS	drug	#drugs	drug class	best drug	p-value
22869	CF;CFZ;TE;CRM	4	polyketide*;Lactams	TE	7.1157E-019
22977	CF;CFZ;TE;CRM	4	polyketide*;Lactams	TE	9.7077E-018
21990	CF;CFZ;TE;CRM	4	polyketide*;Lactams	TE	1.1168E-015
22922	CF;CFZ;CRM	3	Lactams	CRM	2.0983E-011

21985	TE		1	polyketide*	TE	6.6089E-012
22153	CF;CFZ;TE;CRM;AM		5	polyketide*;Lactams	CFZ	5.1962E-021
22982	CF;CFZ;TE;CRM		4	polyketide*;Lactams	TE	7.7442E-039
22952	CF;TE;CFZ;CRM;CP;CAX;AM;A/S;AUG		9	fluoroquinolone;polyketide*;Lactams	TE	5.7464E-041
22983	CF;TE;CFZ;CRM;AM;A/S;AUG		7	polyketide*;Lactams	TE	3.3785E-029
22976	CF;CFZ;TE;CRM;AM		5	polyketide*;Lactams	TE	7.1505E-027
22931	CF;CFZ;TE;CRM;AM		5	polyketide*;Lactams	TE	7.7783E-023
22924	CF;TE;CFZ;CRM;CP;AM;A/S;AUG		8	fluoroquinolone;polyketide*;Lactams	TE	1.0208E-031
22302	CF;CFZ;CRM		3	Lactams	CRM	7.4244E-011
22249	CF;CFZ;CRM		3	Lactams	CRM	4.9240E-011
22975	CF;CFZ;TE;CRM		4	polyketide (tetracycline);Lactams	CRM	2.3707E-015
22151	CF;CFZ;TE;CRM;AM		5	polyketide (tetracycline);Lactams	CFZ	5.1962E-021
21987	CF;CFZ;TE;CRM		4	polyketide (tetracycline);Lactams	TE	3.4107E-015
22010	CF;CFZ;TE;CRM;CAX		5	polyketide (tetracycline);Lactams	TE	2.5512E-037
22853	CF;TE;CFZ;CRM;CP;AM;A/S		7	fluoroquinolone;polyketide*;Lactams	TE	8.5132E-023
22953	CF;TE;CFZ;CRM;CP;AM;A/S;AUG		8	fluoroquinolone;polyketide*;Lactams	TE	4.9906E-037
22164	CF;CFZ;TE;CRM;AM		5	polyketide*;Lactams	CFZ	2.0434E-018
21872	CF;T/S;TE;CFZ;CRM;CP;CAX;LVX;AM;A/S;AUG		11	other (benzene derived)/sulfonamide; polyketide*;fluoroquinolone;Lactams	TE	1.0457E-062
22872	CF;CFZ;TE;CRM;AM		5	polyketide*;Lactams	TE	2.4397E-020
22346	CF;CFZ;TE;CRM		4	polyketide*;Lactams	CFZ	9.3782E-012
22142	CF;TE;CFZ;CRM;CP;AM;A/S		7	fluoroquinolone;polyketide*;Lactams	CFZ	1.0064E-025
21989	TE		1	polyketide*	TE	5.4618E-013

22892	CF;CFZ;CRM		3	Lactams	CRM	1.3318E-010
22306	CF;CFZ;CRM		3	Lactams	CRM	3.0874E-012
22088	CF;TE;CFZ;CRM;CP;CAX;AM;A/S		8	fluoroquinolone;polyketide*;Lactams	TE	2.8725E-047
21993	CF;CFZ;TE;CRM;CAX		5	polyketide*;Lactams	TE	1.3296E-023
22986	CF;TE;CFZ;CRM;AM;A/S;AUG		7	polyketide*;Lactams	TE	1.0911E-030
22248	CFZ;TE;CRM		3	polyketide*;Lactams	CFZ	2.4745E-010
22652	TE		1	polyketide*	TE	2.0483E-011
22864	CF;TE;CFZ;CRM;CP;AM;A/S		7	fluoroquinolone;polyketide*;Lactams	TE	8.5132E-023
21970	CF;CFZ;TE;CRM;CAX		5	polyketide*;Lactams	TE	1.9096E-037
22247	CFZ;TE;CRM		3	polyketide*;Lactams	CFZ	2.4745E-010

*: (tetracycline)

Similar results were obtained for other genes, also the ones in Tables 1 and 2, but are omitted for the sake of brevity. The above genes were chosen as they show very clearly the presence of a multitude of SNPs associated with antibiotic
5 resistance in the respective genes.

Further, a synergistic effect of individual SNPs was demonstrated by exhaustively comparing significance levels for association of single SNPs with antibiotic susceptibil-
10 ity/resistance and significance levels for association of combinations of SNPs with antibiotic susceptibil-
ity/resistance.

For example, a combination of two SNPs for CP resulted in a
15 balanced accuracy of 86.35, whereas the balanced accuracy for single genes was lower than that, e.g. 82.28 for secG at position 3741905, 81.34 for cyoC at position 131826, 81.665 for pykF at position 1482764, and maximally 86.34 for parC at position 2562578.

20 The balanced accuracy is therein defined as the arithmetic mean of sensitivity and specificity = (sensitivity + specificity)/2 with sensitivity = $TP / (TP+FN)$ and specificity = $TN / (TN+FP)$; with TN = true negatives = susceptible and predicted to be susceptible; TP = true positives = resistant and predicted to be resistant; FN = false negatives = resistance, predicted to be susceptible; and FP = false positives = susceptible, predicted to be resistance. It is a better performance estimate than accuracy ($(TP + TN) / (\text{number of samples})$) in case of imbalanced datasets, e.g. if there are
25 much more resistant samples when non-resistant ones or vice versa. In such cases accuracy may be high though the smaller class is not predicted correctly, then balanced accuracy is
30

less biased by the data imbalance (Example: 11 samples are resistant, 51 are susceptible and TP=50, TN=1, FN=1, FP=10. Then accuracy = $(50+1) / 62 = 82.26\%$ and balanced accuracy is $((50/51) + (1/11))/2 = 53.57\%$).

5

Again, similar results were obtained for other SNPs and other antibiotics in respective genes.

Interestingly, it was also observed that the synergistic effect is enhanced for a combination of SNPs in different genes compared to SNPs from the same gene. Specifically, the above shown example reaching the increase to 158% of the original performance was obtained by combining two mutations from two different genes.

15

Although some strains of Proteus are sensitive to ampicillin and cephalosporins, we observed a high resistance against these and other anti-bacterial agents.

20

A genetic test for the combined pathogen identification and antimicrobial susceptibility testing direct from the patient sample can reduce the time-to actionable result significantly from several days to hours, thereby enabling targeted treatment. Furthermore, this approach will not be restricted to central labs, but point of care devices can be developed that allow for respective tests. Such technology along with the present methods and computer program products could revolutionize the care, e.g. in intense care units or for admissions to hospitals in general. Furthermore, even applications like real time outbreak monitoring can be achieved using the present methods.

30

Instead of using only single variants, a combination of several variant positions can improve the prediction accuracy and further reduce false positive findings that are influenced by other factors.

Compared to approaches using MALDI-TOF MS, the present approach has the advantage that it covers almost the complete genome and thus enables us to identify the potential genomic sites that might be related to resistance. While MALDI-TOF MS can also be used to identify point mutations in bacterial proteins, this technology only detects a subset of proteins and of these not all are equally well covered. In addition, the identification and differentiation of certain related strains is not always feasible.

The present method allows computing a best breakpoint for the separation of isolates into resistant and susceptible groups. The inventors designed a flexible software tool that allows to consider - besides the best breakpoints - also values defined by different guidelines (e.g. European and US guidelines), preparing for an application of the GAST in different countries.

The inventors demonstrate that the present approach is capable of identifying mutations in genes that are already known as drug targets, as well as detecting potential new target sites.

The current approach enables

- a. Identification and validation of markers for genetic identification and susceptibility/resistance testing within one diagnostic test

- b. validation of known drug targets and modes of action
- c. detection of potentially novel resistance mechanisms leading to putative novel target / secondary target genes for new therapies

Claims

1. A diagnostic method of determining an infection of a patient with *Proteus* species potentially resistant to antimicrobial drug, e.g. antibiotic, treatment, comprising the steps of:
 - a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
 - 10 b) determining the presence of at least one mutation in at least two genes from the group of genes consisting of *parC*, *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, *PMI2939*, *fdoG*, *PMI3715*, and *gpmB*, wherein the presence of said at least two mutations is indicative of
15 an infection with an antimicrobial drug, e.g. antibiotic, resistant *Proteus* strain in said patient.

2. A method of selecting a treatment of a patient suffering from an infection with a potentially resistant *Proteus* strain, comprising the steps of:
 - a) obtaining or providing a sample containing or suspected of containing at least one *Proteus* species from the patient;
 - b) determining the presence of at least one mutation in at
25 least two genes from the group of genes consisting of *parC*, *secG*, *cyoC*, *pykF*, *flhB*, *dedA*, *crr*, *murF*, *gmhB*, *purH*, *PMI2939*, *fdoG*, *PMI3715*, and *gpmB*, wherein the presence of said at least two mutations is indicative of a resistance to one or more antimicrobial, e.g. antibiotic, drugs;
 - 30 c) identifying said at least one or more antimicrobial, e.g. antibiotic, drugs; and

- d) selecting one or more antimicrobial, e.g. antibiotic, drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.
- 5 3. The method of one or more of the preceding claims, wherein at least a mutation in parC, particularly in position 2562578 with regard to reference genome NC_010554 as annotated at the NCBI, is determined.
- 10 4. The method of one or more of the preceding claims, wherein the method involves determining the resistance of Proteus to one or more antimicrobial, e.g. antibiotic, drugs.
- 15 5. The method of any one of claims 1 to 4, wherein the antimicrobial, e.g. antibiotic, drug is selected from lactam antibiotics and the presence of a mutation in the following genes is determined: parC, secG, cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB; and/or
- 20 wherein the antimicrobial, e.g. antibiotic, drug is selected from quinolone antibiotics, preferably fluoroquinolone antibiotics, and the presence of a mutation in the following genes is determined: parC, secG,
- 25 cyoC, pykF, flhB, dedA, crr, murF, gmhB, purH, PMI2939, fdoG, PMI3715, and/or gpmB; and/or
- 30 wherein the antimicrobial, e.g. antibiotic, drug is selected from aminoglycoside antibiotics, and the presence of a mutation in the following genes is determined: parC; and/or
- wherein the antimicrobial, e.g. antibiotic, drug is selected from polyketide antibiotics, preferably tetracycline antibiotics, and the presence of a mutation in the

following genes is determined: *secG*, *cyoC*, *pykF*, *flhB*,
dedA, *crr*, *murF*, *gmhB*, *purH*, *PMI2939*, *fdoG*, *PMI3715*,
and/or *gpmB*; and/or

wherein the antimicrobial, e.g. antibiotic, drug is se-
lected from benzene derived/sulfonamide antibiotics, and
the presence of a mutation in the following genes is de-
termined: *parC* and/or *fdoG*.

6. The method of one or more of the preceding claims, where-
in the antimicrobial drug, e.g. antibiotic drug, is se-
lected from the group consisting of Amoxicillin/K
Clavulanate (AUG), Ampicillin (AM), Aztreonam (AZT),
Cefazolin (CFZ), Cefepime (CPE), Cefotaxime (CFT),
Ceftazidime (CAZ), Ceftriaxone (CAX), Cefuroxime (CRM),
Cephalotin (CF), Ciprofloxacin (CP), Ertapenem (ETP),
Gentamicin (GM), Imipenem (IMP), Levofloxacin (LVX),
Meropenem (MER), Piperacillin/Tazobactam (P/T), Ampicil-
lin/Sulbactam (A/S), Tetracycline (TE), Tobramycin (TO),
and Trimethoprim/Sulfamethoxazole (T/S).

7. The method of any one of claims 1 to 6, wherein the anti-
biotic drug is at least one of CF, CFZ, CRM, CP, CAX, AM,
A/S, LVX and AUG, and a mutation in at least one of the
following nucleotide positions is detected with regard to
reference genome NC_010554: 2562578, 3741905, 131826,
1482764, 1771087, 1771119, 1918241, 1968294, 2238063,
2238072, 2238088, 2238090, 2454709, 3039125, 3221491,
3221494, 3422635, 4059624, 4059634, 4060202, 131835;
and/or

wherein the antibiotic drug is TE and a mutation in at
least one of the following nucleotide positions is de-
tected with regard to reference genome NC_010554:
3741905, 131826, 1482764, 1771087, 1771119, 1918241,

1968294, 2238063, 2238072, 2238088, 2238090, 2454709,
3039125, 3221491, 3221494, 3422635, 4059624, 4059634,
4060202, 131835; and/or

wherein the antibiotic drug is CFT and a mutation in at
least one of the following nucleotide positions is de-
tected with regard to reference genome NC_010554:

2562578, 3741905, 131826, 1482764, 1771087, 1771119,
1918241, 1968294, 2238063, 2238072, 2238088, 2238090,
3221491, 3221494, 4059624, 4059634, 4060202, 131835;

and/or

wherein the antibiotic drug is T/S and a mutation in at
least one of the following nucleotide positions is de-
tected with regard to reference genome NC_010554:

2562578, 3422635; and/or

wherein the antibiotic drug is at least one of GM and CPE
and a mutation in at least one of the following nucleo-
tide positions is detected with regard to reference ge-
nome NC_010554: 2562578.

8. The method of any one of claims 1 to 7, wherein the re-
sistance of a bacterial microorganism belonging to the
species *Proteus* against 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15 or 16, 17, 18, 19, 20 or 21 antibi-
otic drugs is determined.

9. The method of one or more of the preceding claims, where-
in determining the nucleic acid sequence information or
the presence of a mutation comprises determining a par-
tial sequence or an entire sequence of the at least two
genes.

10. The method of one or more of the preceding claims, where-
in determining the nucleic acid sequence information or

the presence of a mutation comprises determining a partial or entire sequence of the genome of the Proteus species, wherein said partial or entire sequence of the genome comprises at least a partial sequence of said at least two genes.

5

11. The method of one or more of the preceding claims, wherein determining the nucleic acid sequence information or the presence of a mutation comprises using a next generation sequencing or high throughput sequencing method, preferably wherein a partial or entire genome sequence of the bacterial organism of Proteus species is determined by using a next generation sequencing or high throughput sequencing method.

10
15

12. A method of determining an antimicrobial drug, e.g. antibiotic, resistance profile for bacterial microorganisms of Proteus species, comprising:
obtaining or providing a first data set of gene sequences of a plurality of clinical isolates of Proteus species;
providing a second data set of antimicrobial drug, e.g. antibiotic, resistance of the plurality of clinical isolates of Proteus species;
aligning the gene sequences of the first data set to at least one, preferably one, reference genome of Proteus, and/or assembling the gene sequence of the first data set, at least in part;
analyzing the gene sequences of the first data set for genetic variants to obtain a third data set of genetic variants;
correlating the third data set with the second data set and statistically analyzing the correlation; and

20

25

30

determining the genetic sites in the genome of *Proteus* associated with antimicrobial drug, e.g. antibiotic, resistance.

- 5 13. A diagnostic method of determining an infection of a patient with *Proteus* species potentially resistant to antimicrobial drug treatment, comprising the steps of:
- 10 a) obtaining or providing a sample containing or suspected of containing a bacterial microorganism belonging to the species *Proteus* from the patient;
 - 15 b) determining the presence of at least one mutation in at least one gene of the bacterial microorganism belonging to the species *Proteus* as determined by the method of claim 12, wherein the presence of said at least one mutation is indicative of an infection with an antimicrobial drug resistant *Proteus* strain in said patient.
- 20 14. A method of selecting a treatment of a patient suffering from an infection with a potentially resistant *Proteus* strain, comprising the steps of:
- 25 a) obtaining or providing a sample containing or suspected of containing a bacterial microorganism belonging to the species *Proteus* from the patient;
 - b) determining the presence of at least one mutation in at least one gene of the bacterial microorganism belonging to the species *Proteus* as determined by the method of claim 12, wherein the presence of said at least one mutation is indicative of a resistance to one or more antimicrobial drugs;
 - 30 c) identifying said at least one or more antimicrobial drugs; and

d) selecting one or more antimicrobial drugs different from the ones identified in step c) and being suitable for the treatment of a Proteus infection.

- 5 15. A method of acquiring an antimicrobial drug, e.g. antibiotic, resistance profile for bacterial microorganisms of Proteus species, comprising:
obtaining or providing a first data set of gene sequences of a clinical isolate of Proteus species;
10 providing a second data set of antimicrobial drug, e.g. antibiotic, resistance of a plurality of clinical isolates of Proteus species;
aligning the gene sequences of the first data set to at least one, preferably one, reference genome of Proteus,
15 and/or assembling the gene sequence of the first data set, at least in part;
analyzing the gene sequences of the first data set for genetic variants to obtain a third data set of genetic variants of the first data set;
20 correlating the third data set with the second data set and statistically analyzing the correlation; and
determining the genetic sites in the genome of Proteus of the first data set associated with antimicrobial drug, e.g. antibiotic, resistance.
- 25 16. Computer program product comprising computer executable instructions which, when executed, perform a method according to any one of claims 12 to 15.

